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SUMMARY 
 
Metabolic myopathies are a heterogeneous group of diseases characterized by genetically 
determined defects which impair skeletal muscle energy production and/or function. These diseases 
include errors of glycogen metabolism, lipid metabolism, and mitochondrial respiratory chain. The 
most common clinical features are muscle weakness, pain, easy fatigability, cramping and, 
sometimes myoglobinuria due to muscle fiber necrosis. Exercise intolerance is another hallmark of 
clinical features of metabolic myopathies. As a result, patients note undue fatigue and dyspnea 
during low levels of exertion, including moderate activities of daily living. Symptoms are usually 
first experienced in childhood or early adulthood, however, late-onset is well recognized.  
The diagnostic process of these diseases usually begins with a careful medical history, a physical 
and neurological examination to assess reflexes, strength and the distribution of weakness. Creatine 
kinase is an extremely useful laboratory test for the evaluation of patients with a suspected 
myopathy and electromyography may be used to rule out a number of other neuromuscular 
disorders that cause similar patterns of weakness. As for exercise testing, the six minute walking 
test and the forearm ischaemic lactate test have traditionally been employed to screen for suspected 
disorders of glycogen metabolism; however, they have been superseded by improved biochemical 
and genetic techniques. Confirmation of the diagnosis usually requires muscle biopsy and/or 
molecular genetic testing.  
Functional evaluation of oxidative metabolism during exercise provides information regarding the 
physiological responses required by the cardiovascular and respiratory systems to meet the 
metabolic demands of the skeletal muscle. Moreover, the study of the physiological adjustments to 
exercise in patients is of extreme interest also from a “basic science” point of view, allowing to 
investigate aspects related to the regulation and integration of physiological and bioenergetic 
responses. Although exercise testing is widely utilized by cardiology, pulmonary, and sports 
medicine clinicians as a means to assess heart failure, respiratory disease, or athletic capacity, only 
few neurologists utilize a comprehensive assessment of oxidative metabolism to clarify the etiology 
of exercise intolerance and unexplained dyspnea among patients with metabolic myopathies. 
In previous studies our group applied on mitochondrial myopathies (MM) and McArdle’s disease 
(McA) patients two non−invasive methods of functional evaluation specifically aimed at oxidative 
metabolism at the skeletal muscle level. The variables of functional evaluation that we investigated 
were: A) Skeletal muscle oxygenation indices during exercise, obtained by near−infrared 
spectroscopy (NIRS) and taken as estimates of the capacity of O2 extraction; B) Kinetics of 
adjustment of pulmonary O2 uptake (V’O2 kinetics) during the transition from rest to exercise. We 
demonstrated that these methods allow to identify and quantify, in MM and in McA, the metabolic 
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impairment. Moreover, these studies represent a typical example of “translational medicine”, in 
which methods and tools developed over the years in the exercise physiology laboratory are taken 
to the bed of the patient. 
In this thesis will be reported data of four studies in which the above−mentioned tools of functional 
evaluation of muscle oxidative metabolism were utilized, with specific purposes, on patients with 
metabolic myopathies.   
In the first study we evaluated, during a 24-month follow-up, cardiovascular and metabolic 
responses to exercise of a 50-yr-old patient with glycogen storage disease type II (Pompe disease) 
undergoing enzyme replacement therapy (ERT). At the same constant-workload submaximal 
exercise, rate of perceived exertion, pulmonary ventilation, and heart rate were lower during ERT 
versus pre-treatment, suggesting an increased exercise tolerance. Peak oxygen uptake increased by 
approximately 35% after 1 month of treatment and did not significantly change thereafter. Also, 
peak cardiac output significantly increased during ERT, whereas peak skeletal muscle fractional O2 
extraction was unchanged compared with pre-treatment. Thus, this case report suggest that ERT 
may increase peak exercise capacity and exercise tolerance at submaximal workloads in patients 
with glycogen storage disease type II after 1 month of therapy, without no further changes 
occurring up to 24 months.  
In the second study, we followed the same approach of the case study previously mentioned and we 
evaluated the effects of 12-month of ERT on physiological variables related to exercise tolerance of 
four patients with Pompe disease. Patients performed an incremental exercise on a cycle ergometer, 
up to voluntary exhaustion, before and after 12 months of ERT. Peak workload and oxygen uptake 
values significantly increased after ERT whereas the observed increases of both peak cardiac output 
and the NIRS-determined peak skeletal muscle fractional O2 extraction were not statistically 
significant. These findings suggest that in glycogen storage disease type II patients enzyme 
replacement therapy is associated with a mild improvement of exercise tolerance. Since exercise 
training could improve exercise tolerance, motor function and muscle strength, counteracting the 
general deconditioning typical of chronic diseases, in the future may be interesting to evaluate if 
exercise training could be helpful in increasing ERT clinical efficacy, improving patients' muscle 
function and ameliorating their quality of life. A new study based upon a collaboration between 
neurologists and exercise physiologists has now started and it should give the opportunity to better 
investigate crucial issues related to patients’ follow-up and treatment. 
In the third study we evaluated in McArdle’s (McA) patients whether a first bout of exercise 
determines a sudden decrease in heart rate (HR) and an improved exercise tolerance (the so-called 
“second-wind” phenomenon) during a second bout, separated by the first by a few minutes of 
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recovery. A second-wind phenomenon (marked decrease in heart rate and in the rating of perceived 
exertion) was indeed observed in McA patients during the second of two consecutive 6-min 
constant-work rate submaximal exercises. The second wind was associated with changes of 
physiological variables, suggesting an enhanced skeletal muscle oxidative metabolism: enhanced O2 
extraction; signs of better matching between intramuscular O2 delivery and O2 utilization; 
disappearance of the “slow component” of pulmonary VO2 kinetics. The second wind was not 
described in McA patients after a longer (18-min) recovery period or in patients affected by a 
mitochondrial myopathy who have similar exercise intolerance. Besides being of interest from a 
basic science point of view (elucidating the mechanisms responsible for the second wind in McA 
patients), results of the present study are of interest also from a clinical point of view, since they 
identify a method (a warm up moderate-intensity exercise, carried out a few minutes before 
performing a task) capable of significantly increasing exercise tolerance in these patients. 
Finally, still unpublished data of another study are presented in this thesis, demonstrating the utility 
of non−invasive functional evaluation methods utilized by physiologists in the follow−up of 
patients as well as in the evaluation of the effects of therapies and/or rehabilitation intervention (i.e. 
exercise training). Since at present the therapeutic interventions available for metabolic myopathies 
patients are very limited and evidence from the literature suggests that moderate−intensity aerobic 
exercise training represents a safe intervention, the variables of functional evaluation determined by 
the above−mentioned tools were utilized to evaluate, in MM and McA patients, the effects of a 
program of moderate−intensity aerobic exercise training carried out by the patients at their home. 
Peak O2 uptake, variable evaluating maximal aerobic power, and peak skeletal muscle (vastus 
lateralis) fractional O2 extraction, as estimated by near-infrared spectroscopy (NIRS), increased 
significantly with training both in MM and in McA. Thus, training induced an increase of exercise 
tolerance at least in part due to a reduction of the impaired fractional O2 extraction by skeletal 
muscles. Moreover, training significantly speeded the V’O2 kinetics, even though only in the 
patients who had presented, before training, markedly slow V’O2 kinetics (i.e. sign of the most 
pronounced metabolic impairment). Surprisingly, the improvements in exercise tolerance obtained 
by the training program did not determine an increase in the habitual level of physical activity 
evaluated a couple of months after the termination of the training program. 
Overall, the results of the studies reported in this thesis demonstrate that, within a translational 
approach, a combination of traditional and more innovative functional evaluation methods can 
effectively detect the functional improvements of patients with metabolic myopathies following 
pharmacological and/or exercise interventions, yielding insights also on the mechanisms of the 
improvements at the pathophysiological level. Thus, functional evaluation of oxidative metabolism 
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by non−invasive methods could be usefully employed in the diagnostic process of metabolic 
myopathies, in the follow−up of patients, and in the evaluation of the effects of therapies and/or 
rehabilitation interventions. Moreover, the analysis of the physiological and bioenergetics 
adaptations to exercise in patients with metabolic myopathies represents an interesting model to 
investigate and elucidate, in vivo, the regulation of basic physiological processes.  
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DEFINITION OF METABILIC MYOPATHY 
Muscle function can be disturbed by exogenous influences impinging on the muscle (e.g., physical 
trauma, toxic substances, infectious organisms, and endocrine and other systemic disorders), as well 
as by inherited defects in its structure and biochemistry. Any disorder in which muscle dysfunction 
arises from some genetic defect in muscle itself or from damage directly to the muscle is termed a 
myopathy (Mastaglia, FL and Detchant, Lord Walton (eds): Skeletal Muscle Pathology, ed 2. Churchill living- stone, Edinburgh, 1992 - Riggs, 
JE and Schocher, SS, Jr: Muscle Disease. Chapter 53. In Joynt, RJ (ed): Clinical Neurology, vol 4. JB Lippincott, Philadelphia, 1991). 
Disorders in which muscle function is impaired by neural elements do not constitute myopathies. 
Under the heading “Metabolic Myopathies,” we consider inborn errors of glycogen metabolism, 
lipid metabolism, and the mitochondrial respiratory chain (RC) (DiMamo, S: Metabolic Myopathies. Chapter 10. In 
Adachi, M and Sher, JH(eds): Neuromuscular Dis- ease. 19aku-Shoin, New York, 1990). Thus, metabolic myopathies are a 
group of genetic disorders that result from the inability of skeletal muscle to produce or maintain 
adequate levels of energy (ATP). These diseases are different from myopathies induced by 
medications that can impair muscle intermediary metabolism (i.e., statins(Baker SK, Vladutiu GD, Peltier WL, et 
al. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci. 2008;35:94–97), which are generally 
grouped within the category of toxic myopathies.  
The first published case report of a ‘‘metabolic myopathy,’’ was described by McArdle in 1951 
(McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci. 1951;24:13–36). Since then, the knowledge of the 
pathophysiology of metabolic myopathies has significantly improved and today an identification of 
the most common genetic and biochemical defects of these disorders is possible (Hirano M, DiMauro S. 
Metabolic myopathies. Adv Neurol. 2002;88:217–234).  
The metabolic myopathies are generally classified according to the altered area of metabolism and 
can be divided into muscle glycogenoses, disorders of lipid metabolism and mitochondrial 
myopathies. To understand this diverse group of diseases, it is helpful to briefly review normal 
muscle physiology. During exercise, the working muscle needs a continuous supply of adenosine 
triphosphate (ATP), but the initial stores of ATP in the muscles are used up very quickly or 
preserved for other functions (i.e. electrochemical equilibrium). Therefore, ATP must be 
regenerated. The resynthesis of ATP involves three energy systems (Fig. 1).  
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Figure 1. The three energy systems of muscle ATP regeneration. 
 
The first energy source is the high-energy phosphagen system, which is characterized by the use of 
phosphocreatine (PCr) as a substrate. The initial concentrations of ATP and PCr, which are low and 
are depleted rapidly in high-intensity work in the muscle, are limiting factors for the high-energy 
phosphate system. Therefore, this system, which is able to produce very large amounts of energy in 
a short duration of time, can provide energy for muscles in the initial 1 to 15 s of high-intensity 
activity (Hultman E, Bergstrom J, Anderson NM (1967) Breakdown and resynthesis of phosphorylcreatine and adenosine triphosphate in 
connection with muscular work in man. Scand J Clin Lab Invest 19:56–66). This means that after this short period of time, 
ATP resynthesis must occur through the other two main energy systems: anaerobic glycolysis or 
aerobic oxidation. In anaerobic glycolysis, energy is released from the catabolism of muscle storage 
glycogen or blood glucose to pyruvate (Hargreaves M (2000) Skeletal muscle metabolism during exercise in humans. Clin Exp 
Pharmacol Physiol 27:225–228). Under anaerobic conditions, when the work output is over 25–30% of 
maximum voluntary contraction (MVC), glycogen represents the main source of ATP. The third 
energy source is the aerobic oxidative energy system, which is the main ATP supply during 
exercise activities performed for several minutes. Limiting factors for this system are sufficient 
tissue amount of mitochondria, oxygen availability, and the presence of the enzymes involved in the 
metabolic pathway. Blood lactate levels remain relatively low during purely aerobic exercise. 
During the recovery period after exercise, the oxidative metabolism is the only source for the re-
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synthesis of PCr and ATP. Moreover, lactate is picked up from blood by type I fibers, where it is 
converted back to pyruvate, which enters the Krebs cycle (Fig. 2). 
 
Figure 2. Skeletal muscle bioenergetics  
 
Thus, metabolic myopathies include either disorders of glycogen/glucose metabolism or disorders 
of lipid metabolism whereas mitochondrial myopathies encompass disorders that impair both fat 
and carbohydrate metabolism and restrict oxidative phosphorylation. As for abnormalities of 
glycogen metabolism (Glycogenoses - GSD), several defects throughout the cascade of enzymes 
and substrates that split glycogen to pyruvate have been identified (Table 1). Moreover, there could 
also be defects in the glycogen degradation process. In most of these disorders skeletal muscle is 
affected to some extent (types V, VII, X, and XI). In other disorders the enzymatic defect is more 
generalized and symptoms arising in other systems predominate, especially in the liver.  
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Table 1. Disorders of glycogen metabolism affecting muscle (DiMauro S. Muscle glycogenoses: an overview. 
Acta Myol 2007; 26:35–41) 
 
The diseases impairing lipid metabolism ultimately impair β-oxidation of lipid within the 
mitochondrial matrix. The main defects that have been identified include transport of long-chain fat 
across the mitochondrial membrane (i.e., CPT deficiency) or transport of carnitine into the cell (ie, 
carnitine transporter deficiency), and mutations in β-oxidation enzymes directly [ie, long-chain 
acyl-CoA dehydrogenase, medium-chain acyl-CoA dehydrogenase, trifunctional protein, 
deficiency]. The more severe variants present in infancy or childhood with a primary liver or 
encephalopathy picture, whereas the adult-onset forms are predominately myopathic (Tein I. Metabolic 
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myopathies. Semin Pediatr Neurol. 1996;3:59–98). Mitochondrial myopathies represent a diverse group of 
conditions with a primary defect in electron transport chain function (Fig. 3). These disease include 
myopathies caused by primary mtDNA mutations, nuclear mutations that lead to multiple mtDNA 
deletions or depletion, and nuclear mutations that impair the synthesis of individual respiratory 
chain subunits or mitochondrial protein synthesis (DiMauro, S., Schon, E. A., Carelli, V., et al. The clinical maze of 
mitochondrial neurology. Nat Rev Neurol. 2013; 9( 8): 429– 444). 
 
Figure 3. Schematic illustration of the mitochondrial electron transport chain and the relative 
contribution of subunits encoded by mtDNA and nuclear DNA (nDNA). 
 
POMPE DISEASE 
Pompe disease (GSD II or acid maltase deficiency) is an autosomal recessive disorder caused by 
deficiency of the lysosomal enzyme acid-α-glucosidase (GAA) which catalyzes the hydrolysis of α-
1,4 and α-1,6 links of glycogen. The enzyme deficiency leads to lysosomal accumulation of 
glycogen and disruption of tissue architecture in different organs, especially the skeletal muscles, 
heart and liver. The continuum spectrum of clinical phenotypes ranges from an infantile-onset 
rapidly fatal form to a slowly progressive adult form (R. Hirschhorn, A.J. Reuser, Glycogen storage disease type II: acid 
alpha glucosidase deficiency, in: B.A. Scriver, W. Sly, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 8th edition, 
McGraw-Hill, New York, 2001, pp. 3389–3420). The classic infantile-onset form, usually owing to complete GAA 
deficiency, presents in the first months of life with generalized marked hypotonia and muscle 
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weakness, severe cardiomyopathy, feeding difficulties, failure to thrive, and respiratory failure. 
Untreated patients die within the first year of life of cardiorespiratory dysfunction (P. Laforêt, M. Nicolino, 
P.B. Eymard, J.P. Puech, C. Caillaud, L. Poenaru, M. Fardeau, Juvenile and adult-onset acid maltase deficiency in France: genotype–phenotype 
correlation, Neurology 55 (8) (2000) 1122–1128). In the juvenile forms symptoms appear between 2 and 5 years of 
age, and cardiomyopathy is rarely seen. The adult forms, named late-onset GSDII and usually 
characterized by residual enzyme activity, are slowly progressive myopathies that leads to a 
progressive loss of motor function. Diaphragmatic weakness and respiratory insufficiency are 
frequent and induce early restrictive respiratory insufficiency (M.L. Hagemans, W.J. Hop, P.A. Van Doorn, A.J. 
Reuser, A.T. Van der Ploeg, Course of disability and respiratory function in untreated late onset Pompe disease, Neurology 66 (4) (2006) 581–583). 
Cardiac involvement is rarely reported in adult patients. When present, it is usually less severe than 
infantile patients and is characterized by cardiac hypertrophy (involving the left ventricular wall or 
the ventricular septum) and conduction abnormalities. In untreated late-onset patients, muscle 
strength and pulmonary function usually deteriorate over the years, leading to wheelchair use and 
respiratory support in most of cases; it has been demonstrated that untreated adult GSDII patients 
present an invariably progressive disease, have higher mortality compared with the general 
population, and present a poor quality of life (D. Gungor, J.M. de Vries,W.C. Hop, A.J. Reuser, P.A. van Doorn, A.T. van der 
Ploeg,M.L. Hagemans, Survival and associated factors in 268 adultswith Pompe disease prior to treatment with enzyme replacement therapy, 
Orphanet J. Rare Dis. 6 (2011) 34). Genetic testing and the blood spot enzymology testing serve as diagnostic 
tests, although a confirmatory muscle biopsy is sometimes required. The histopathological hallmark 
of Pompe disease is increased muscle fiber vacuolization and autophagy (Fig. 4).  
 
 
Figure 4. Muscle biopsy of a late-onset GSDII patient: (a) fiber vacuolization (H&E); (b) 
PAS-positive vacuoles (PAS reaction); (c) increased autophagy (acid phosphatase); 
 
The vacuoles vary in size and shape and show PAS-positivity and strong reaction for lysosomal 
acid phosphatase. Most of the infantile and childhood-onset forms typically exhibit fibers occupied 
by huge vacuoles that contain basophilic amorphous PAS positive materials. In late-onset patients 
the degree of vacuolization is extremely variable and it appears sometimes independent of age of 
onset, disease duration, or clinical features. Acid phosphatase positive globular inclusions can be 
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found in a small proportion of patients with adult-onset Pompe disease, and have been proposed as 
a hallmark of Pompe disease and a useful diagnostic marker when typical vacuolated fibers are 
lacking (Raben N, Roberts A, Plotz PH: Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007, 26:45-48). Genotype– 
phenotype correlations showed that the disease phenotype is hard to predict on the basis of gene 
mutations alone, in most cases, even if the nature of the mutation sometimes matches the clinical 
phenotype. A role of the genetic background and a modifying effect of exogenous factors on GAA 
gene expression is present and shifts the enzyme biosynthesis and degradation rate. Several enzyme 
replacement therapies (ERT) have been tried in GSDII patients since 1967, when the enzyme 
derived from Aspergillus niger was unsuccessfully tested (Hug G, Schubert WK: Lysosomes in type II glycogenosis. 
Changes during administration of extract from Aspergillus niger. J Cell Biol 1967, 35:C1-C6). The first effective approach to the ERT 
was the rhGAA (Myozyme) derived from hamster ovary cells. The treatment was soon 
demonstrated to be effective in infantile patients in markedly reducing left ventricular mass and 
improving cardiomyopathy, which are the hallmark of infantile form and the primary cause of death 
of infant patients. Furthermore, rhGAA treatment reduced the risk of death and of invasive 
ventilation, compared with an untreated control group (P.S.Kishnani, M.Nicolino, T.Voit, R.C. Rogers,A.C. Tsai, 
J.Waterson,G.E.Herman, A. Amalfitano, B.L. Thurberg, S.Richards,M. Davison, D. Corzo, Y.T. Chen, Chinese hamster ovary cell-derived 
recombinant human acid a-glucosidase in infantile-onset Pompe disease, J. Pediatr. 149 (2006) 89–97). In adult GSDII patients is 
difficult to define the impact of therapies due to the slowly progressing nature of the disease and the 
wide variability of organ involvement. The only randomized placebo-controlled study is the LOTS 
(Late Onset Treatment Study), in which 90 patients between 10 and 70 years of age were treated 
with rhGAA (60 patients) or placebo (30 cases) for 18 months (A.T. van der Ploeg, P.R. Clemens, D. Corzo, D.M. 
Escolar, J. Florence, G.J. Groeneveld, S. Herson, P.S. Kishnani, P. Laforet, S.L. Lake, D.J. Lange, R.T. Leshner, J.E. Mayhew, C. Morgan, K. 
Nozaki, D.J. Park, A. Pestronk, B. Rosenbloom, A. Skrinar, C.I. van Capelle, N.A. van der Beek, M. Wasserstein, S.A. Zivkovic, A randomized study 
of alglucosidase alfa in late-onset Pompe disease, N. Engl. J. Med. 362 (15) (2010) 1396–1406). The treatment improved walking 
distance measured with the 6-minute walk (6-MWT) test of 65 m and stabilized pulmonary function 
in the rhGAA group, as compared to the slight worsening of walked distance and respiratory 
function observed in the placebo group. Nevertheless other open-label studies evidenced a rather 
variable course of neuromuscular outcomes in adult onset GSDII patients during long observational 
periods of ERT, demonstrating a variable effect in prolonging walked distance and respiratory 
function. Thus, it is clear that ERT is effective in infantile form, especially for reducing 
cardiomegaly and prolonging children’s survival. On the contrary, in late-onset GSDII it is not easy 
to demonstrate treatment efficacy both on the slowly progressive motor impairment and respiratory 
failure. The analysis of clinical efficacy in adult patients evidenced that the motor response is 
widely variable in each patient. For a better evaluation of natural course and treatment efficacy, 
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accurate quantitative outcome measures should be defined. Indeed, excluding the manual muscle 
testing for muscle strength, the examination of patients usually includes a series of functional tests, 
such as the 6-MWT, and the timed tests, such as the GSGC score (Gait, climbing Stairs, Gowers' 
maneuver and arise form a Chair), which are not very sensitive to underline small differences in the 
clinical course of treated and untreated patients (C. Angelini, C. Semplicini, S. Ravaglia,M.Moggio, G.P. Comi, 
O.Musumeci, E. Pegoraro, P. Tonin, M. Filosto, S. Servidei, L.Morandi,G. Crescimanno, G.Marrosu,G. Siciliano, T. Mongini, A. Toscano, Italian 
Group on GSDII, Newmotor outcome functionmeasures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy, 
Muscle Nerve 45 (6) (2012) 831–834). An increasing role in the evaluation of muscle disease has been acquired 
by muscle MRI, a non-invasive exam that can evaluate muscle mass and fibro-fatty muscle 
degeneration, and, when associated with spectroscopic studies, it may measure glycogen content 
(R.Y. Carlier, P. Laforet, C.Wary, D.Mompoint, K. Laloui, N. Pellegrini, D. Annane, P.G. Carlier, D. Orlikowski,Whole bodymuscle MRI in 20 
patients suffering from late onset Pompe disease: involvement patterns, Neuromuscul. Disord. 21 (2011) 791–799). The identification of 
the factors underlying the variability of clinical response to ERT needs further investigation. In the 
meantime, other therapeutical options have been tried. A dietary treatment with high-protein and 
low-carbohydrates, supplemented with L-alanine, and physical aerobic submaximal exercise was 
proposed (Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, Martiniuk F: Modification of the natural history of adult-onset 
acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35:70-77). The purpose was to decrease the 
deposition of glycogen in lysosomes, and to antagonize the muscle protein catabolism typical of 
GSDII patients, with the dietary treatment, and stimulate fatty acid utilization in muscles like 
energy resource with aerobic exercise. The clinical outcome in one study was surprisingly good, 
even if the compliance to the scheme was not easy, and the increase in the weight of some patients 
worsens their motor function. 
 
McARDLE DISEASE 
McArdle disease (Glycogenosis type V - GSD V), or myophosphorylase deficiency is a disorder of 
skeletal muscle carbohydrate metabolism first described by Brian McArdle in 1951 (McArdle B. Myopathy 
due to a defect in muscle glycogen breakdown. Clin Sci. 1951;10:20). It is one of the most frequent genetic myopathies 
and it is due to an autosomal recessive mutation in both copies of the gene PYGM, encoding the 
muscle isoform of glycogen phosphorylase, myophosphorylase (Bruno C, Cassandrini D, Martinuzzi A, et al. 
McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mut. 2006;27(7):718). Because myophosphorylase 
catalyzes and regulates the breakdown of glycogen into glucose-1-phosphate in muscle fibers, 
patients are unable to obtain energy from their muscle glycogen stores (Di Mauro S. Muscle glycogenoses: an 
overview. Acta Myol. 2007;26(1):35–41). Thus, glycolysis is blocked upstream and the muscle fibers of 
McArdle disease patients can take up glucose from the blood and convert it into glucose-6-
phosphate, which then enters the downstream steps of glycolysis. Muscle glycolysis is not, 
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therefore, totally impaired in these patients. The reduction of pyruvate production in the 
tricarboxylic acid cycle, and the subsequent oxidative phosphorylation impairment bring to 
reduction of AcetylCoA production also with a worsening of function of the breakdown of fatty 
acid. Exercise intolerance is present virtually in all patients and often starts during childhood. For 
example, 58 % of patients reported that symptoms started in the first decade of life, but others 
reported that they appeared later in life (i.e. 28 % in the second decade and 14 % in the third or 
fourth decade) (Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national 
registry. J Neurol Neurosurg Psychiatry. 2012;83(3):322–8). Exercise intolerance typically consists of acute crises of 
early fatigue and muscle stiffness and contractures, especially at the start of exercise, which usually 
disappear if exercise is stopped or intensity is reduced (Fig. 5).  
 
Figure 5. The pathophysiology of exercise intolerance and muscle damage in McArdle disease. 
 
A unique feature of the disease is the so-called ‘second wind’ phenomenon, which most patients 
refer to as the ability to resume dynamic, large-mass exercise (e.g. brisk walking) if they take a 
brief rest upon the appearance of premature fatigue early in exercise (Haller RG, Vissing J. Spontaneous, ‘‘second 
wind’’ and glucoseinduced second ‘‘second wind’’ in McArdle disease: oxidative mechanisms. Arch Neurol. 2002;59(9):1395–402). The first 
few minutes of exercise act as a warm-up (e.g. inducing muscle vasodilation), after which more 
circulating free-fatty acids as well as glucose are available to working muscle fibers that can oxidize 
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these substrates, leading to attenuation of exercise intolerance. However, in these patients episodes 
of marked muscle damage or rhabdomyolysis are not rare. Thus, high serum CK activity (typically[ 
1,000 U/L) triggered by exercise is a common finding which can be accompanied by 
myoglobinuria, typically referred to as ‘dark urine’ (Di Mauro SHA, Tsujino S. Nonlysosomal glycogenoses. In: Engel 
AGFAC, editor. Myology. New York: McGraw-Hill; 2004. p. 1535–58). The main potential danger of exertional 
rhabdomyolysis is acute renal failure as well as hyperkalemia, with the former eventually leading to 
chronic renal failure, although reported cases of life-threatening situations are very scarce. The 
intensity of the stimuli causing intolerance also shows inter-individual variability; in some rare 
cases (fittest patients) symptoms are triggered only by sports participation, whereas most people 
show intolerance to almost all types of physical exercise, and 25 % of patients also report functional 
limitations during daily life activities such as household tasks, personal care, lifting/carrying 
weights during shopping, or carrying children (Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of 
McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83(3):322–8). Patients often show an 
abnormally high cardiac output and heart rate at a given workload during dynamic exercise (Grassi B, 
Porcelli S, Marzorati M, Lanfranconi F, Vago P, Marconi C, Morandi L. Metabolic myopathies: functional evaluation by analysis of oxygen uptake 
kinetics. Med Sci Sports Exerc 41: 2120–2127, 2009). This ‘hyperkinetic’ circulation could be mediated by the local 
effects of potassium, inorganic phosphate, or adenosine, or a combination of these substances, 
released excessively from working skeletal muscles on metabolically sensitive skeletal muscle 
afferents and vascular smooth muscle (Haller RG, Lewis SF, Cook JD, et al. Hyperkinetic circulation during exercise in 
neuromuscular disease. Neurology. 1983;33(10):1283–7). The abnormal cardiovascular response to dynamic exercise 
in these patients could also be due, at least in part, to an altered central motor pattern, which may 
manifest as exaggerated motor unit recruitment for a given workload. As for impaired sympathetic 
nervous system activity, previous research has shown that these patients have normal muscle 
sympathetic nerve responses to exertion, at least for static (handgrip) exercise (Vissing J, Vissing SF, 
MacLean DA, et al. Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies. J 
Clin Invest. 1998;101:1654–60). Despite symptoms of exercise intolerance from early childhood, the 
diagnosis is almost never made in the first decade of life; in approximately 50% of cases, the 
diagnosis is delayed until the fourth decade or later (Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features 
of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry 2012;83(3):322–8). Generally, diagnostic 
testing is undertaken only after a sentinel event, such as an episode of rhabdomyolysis and 
myoglobinuria or after the discovery of an otherwise unexplained elevated serum CK level, which 
commonly is 5 to 10 times the upper limit of normal. Recognition of the characteristic history of 
exercise intolerance is key to undertaking appropriate diagnostic testing. Non-ischemic forearm 
exercise testing is recommended (instead of ischemic exercise, which triggers a muscle contracture) 
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to demonstrate the block in glycogenolysis by absent lactate and increased ammonia production. 
The final diagnosis is usually reached by routine phosphorylase histochemistry and genetic testing 
on muscle biopsy.  
Many drugs or dietary treatments have been tested to alleviate symptoms in this rare disease, but 
most of them failed to demonstrate a significant amelioration or were not well tolerated. No 
significant beneficial effects have been reported in McArdle disease patients receiving branched 
chain amino acids supplementation or fatty acid-rich diet to provide alternative energy sources to 
glycolytic metabolism. High-dose oral ribose (Steele IC, Patterson VH, Nicholls DP. A double blind, placebo controlled, 
crossover trial of D-ribose in McArdle’s disease. J Neurol Sci. 1996;136(1–2):174–7) or vitamin B6 (Phoenix J, Hopkins P, Bartram C, et al. 
Effect of vitamin B6 supplementation in McArdle’s disease: a strategic case study. Neuromuscul Disord. 1998;8(3–4):210–2) failed to 
improve exercise tolerance in McArdle patients. More controversial are the results for creatine 
supplementation: low-dose supplementation (60 mg/kg/day for 4 weeks) attenuated muscle 
complaints in five of nine McArdle disease patients tested, but higher doses (150 mg/kg/day) 
increase intracellular phosphocreatine and actually increased exercise-induced myalgia (Vorgerd M, 
Zange J, Kley R, Grehl T, Hu¨ sing A, Ja¨ ger M, Mu¨ ller K, Schro¨ der R, Mortier W, Fabian K et al.: Effect of high-dose creatine therapy on 
symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 2002, 5:97-101). A 
beneficial intervention for alleviating exercise intolerance symptoms and ‘protecting’ the muscle 
from rhabdomyolysis risk consists of ensuring that sufficient blood glucose (derived from high 
hepatic glycogen stores) is constantly made available to patients’ muscles during the daytime. This 
can be effectively achieved by adopting a diet with a high proportion (65%) of complex 
carbohydrates (such as those found in vegetables, fruits, cereals, bread, pasta and rice) and a low 
proportion (20 %) of fat [132 ]. Another strategy is the ingestion of simple carbohydrates before 
engaging in strenuous exercise: (a) in adults, 75 g of sucrose 30–40 min pre-exercise (Vissing J, Haller 
RG. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med. 2003;349(26):2503–9), or lower 
doses (30–40 g of glucose, fructose or sucrose, which translates to 400–500 mL of most 
commercially available sport drinks) closer to the start of exertion (Andersen ST, Haller RG, Vissing J. Effect of 
oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol. 2008;65(6):786–9); and (b) in children, 20 g 
during the warm-up period preceding any vigorous exercise bout (Perez M, Mate-Munoz JL, Foster C, et al. Exercise 
capacity in a child with McArdle disease. J Child Neurol. 2007;22(7):880–2). Since individual differences in patients’ 
physical activity levels seem to explain the heterogeneity in disease severity, it has been 
hypothesized that exercise training can reduce exercise intolerance of McArdle patients. Although 
evidence from randomized controlled studies is still missing, there is data from interventional 
research showing that patients with McArdle disease,  adapt favorably to regular exercise and show 
an amelioration of clinical symptoms (Haller RG, Wyrick P, Taivassalo T, Vissing J (2006) Aerobic conditioning: an effective 
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therapy in McArdle’s disease. Ann Neurol 59:922–928; Mate-Munoz JL, Moran M, Perez M et al (2007) Favorable responses to acute and chronic 
exercise in McArdle patients. Clin J Sport Med 17:297–303). It must be considered that vigorous dynamic (‘aerobic’) 
exercise should only be performed by the more habituated patients, while intense exercises 
involving high loads on low muscle mass should be generally discouraged. Moreover, pre-exercise 
carbohydrate ingestion might be suggested in order to attenuate the feelings of early fatigue and 
discomfort during the first minutes of a training session.  
 
MITOCHONDRIAL MYOPATHIES 
Mitochondrial myopathies have an estimated prevalence of 10 to 15 cases per 100,000 persons and 
are genetically determined disorders that result from a primary defect of the mitochondrial 
respiratory chain (Fig. 6). The number of defects responsible is experiencing exponential growth 
and now includes myopathies caused by primary mtDNA mutations or nuclear mutations that 
disrupt the function of individual respiratory chain subunits (DiMauro S, Schon EA, Carelli V, et al. The clinical maze 
of mitochondrial neurology. Nat Rev Neurol 2013;9(8):429–44). mtDNA mutations involves genes that encode 
polypeptide subunits of the respiratory chain or transfer or ribosomal RNAs that mediate the 
synthesis of entire mitochondrial proteins (DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 
2003;348:2656–2668). These mtDNA mutations are usually inherited through maternal transmission and 
are thus expressed in a heteroplasmic fashion in cells and tissues, impairing respiratory chain 
function only when the percentage of mutant mtDNA reaches a critical threshold. Mutations in 
nuclear genes usually affect the central or peripheral nervous systems in addition to muscle function 
impairment and cardiac dysfunction is also often present. In the minority of cases it is possible to 
identify a well-defined clinical syndrome such as Kearns-Sayre syndrome (KSS), mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy 
with ragged red fibers (MERRF) or mitochondrial neuro-gastrointestinal encephalopathy (MNGIE) 
disease. 
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Figure 6. Mitochondrial respiratory chain complexes (A) and mitochondrial DNA (D). (B) and 
(C) are serial sections of muscle from a patient with a heteroplasmic mtDNA mutation. 
 
Clinical features of these disorders include a proximal myopathy, stroke-like episodes, seizures, 
ataxia, cognitive decline, axonal neuropathy, sensorineural hearing loss, hypertrophic 
cardiomyopathy, pigmentary retinopathy, diabetes mellitus, short stature, and renal tubular acidosis. 
A number of diverse syndromes are characterized by specific combinations of these clinical 
features. Predominant involvement of one system can also occur. Muscle involvement is present in 
the majority of mitochondrial diseases and varied in its clinical presentation. Chronic progressive 
external ophthalmoplegia and eyelid ptosis often precede or accompany the skeletal muscle disease 
(Nardin RA, Johns DR. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001;24:170–191). Mild weakness of the 
proximal limb musculature is usually present and is made worse by exertion. Patients often note 
myalgias and premature fatigue during exercise. Headache and nausea may occur during strenuous 
activity. More severe defects of oxidative phosphorylation result in a disparity between oxygen 
delivery and oxygen utilization and a hyperdynamic cardiopulmonary response to exercise. Patients 
thus experience marked tachycardia and exertional dyspnea when they engage in submaximal 
exercise. The age at onset of symptoms ranges from birth to late life, but is usually childhood or 
early adult life. Serum CK levels are normal or only mildly elevated. Electromyography usually 
shows mild myopathic or neuropathic changes, or a combination of both. An elevated resting and 
fasting lactate level (> 2.5 mmol/L) in the blood has high specificity but only modest sensitivity for 
the diagnosis (Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports 
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Exerc 2005;37:2086–2093). Exercise testing using a cycle ergometer typically shows a reduction in maximal 
whole body oxygen consumption due to a reduction in peripheral oxygen extraction and a 
disproportionately greater production of carbon dioxide relative to oxygen consumption (Grassi B, 
Porcelli S, Marzorati M, Lanfranconi F, Vago P, Marconi C, Morandi L. Metabolic myopathies: functional evaluation by analysis of oxygen uptake 
kinetics. Med Sci Sports Exerc 41: 2120–2127, 2009). Muscle biopsy is required for specific diagnosis and it is 
typically performed from a limb muscle, such as the quadriceps femoris or deltoid. The major 
histochemical diagnostic feature is the presence of fibers deficient in cytochrome c oxidase activity 
(COX; complex IV of the respiratory chain), which represents low COX activity. COX-negative 
fibers are best identified by serially staining muscle for COX followed by SDH, which stains for 
complex II. The demonstration of COX-deficient, SDH-positive muscle fibers may have the best 
sensitivity and specificity for mitochondrial disease, particularly in adults.  The subsarcolemmal 
accumulation of mitochondria, demonstrated by SDH histochemistry (ragged blue fibers), is another 
classical feature of mitochondrial myopathy. 
 Figure 7. Muscle pathology in mitochondrial disorders. 20-µm cryostat sections of quadriceps 
skeletal muscle. (A) Hematoxylin and eosin, showing increased angulation of the muscle fibers and 
an increase in the proportion of internal nuclei. (B) Succinate dehydrogenase (SDH) histochemistry 
in a patient with a heteroplasmic mtDNA defect, showing subsarcolemmal proliferation of 
mitochondria. (C) Higher power view of SDH histochemistry showing a classical ragged red fiber. 
(D) Ragged red fiber shown by Gomori trichrome staining. (E) Cytochrome c oxidase (COX) 
histochemistry in a normal subject. (F) Global reduction in COX activity seen in a patient with a 
nuclear gene defect. (G) Mosaic COX defect demonstrated by sequential COX-SDH histochemistry 
in a patient with a heteroplasmic pathogenic mtDNA mutation. (H) COX-SDH histochemistry from 
an aged subject showing a single COX-deficient muscle fiber (based on Greenfields Pathology, 9th 
Edition). 
 
Electron microscopy (EM) of muscle may demonstrate enlarged pleiomorphic mitochondria and 
paracrystalline inclusions. However, it provides minor support for the diagnosis of mitochondrial 
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disease because the findings are often nonspecific. Diagnostic information can also be obtained 
from respiratory chain enzyme analysis. Demonstrating a defect is an important diagnostic step in 
patients with normal or near-normal muscle histochemistry, particularly children. Biochemical 
assessment of respiratory chain function in muscle tissue is often coupled with molecular genetic 
studies (Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 
2004;14:237–245). The standard approach is to screen for common mtDNA point mutations using allele-
specific assays or targeted sequencing, and to screen for mtDNA deletions using long-range 
polymerase chain reaction, or Southern blotting. Mutations in nDNA, when present, are always 
detectable from leucocyte DNA. 
As for treatments, a recent Cochrane systematic review of all case series and treatment trials in 
mitochondrial diseases concluded that there were no treatments of proven benefit to influence the 
outcome of the disorder (Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. 
Cochrane Database Syst Rev. 2012 Apr 18;4:CD004426). Thus, the clinical management of mitochondrial disorders 
concentrates on supportive therapy, and symptomatic management of disease complications, such 
as those mentioned in the preceding section. Therapeutic agents to date have focused on various 
nutritional supplements, including carnitine, creatine, CoQ10, cysteine, dichloroacetate, 
dimethyglycine, and the combination of creatine, CoQ10, and lipoic acid, which have been 
evaluated in controlled trials. Various other agents including ascorbate and menadione, high-fat 
diet, magnesium, nicotinamide, and succinate have been of benefit in case reports, but further study 
would be required to indicate whether they are beneficial. Although there are no specific trials 
showing objective evidence of clinical efficacy, patients with a predominantly myopathic 
presentation should have muscle CoQ10 measurements performed, because patients with CoQ10 
biosynthetic defects may respond to CoQ10 supplementation (Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, 
Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007 Feb;35(2):235–
242). For patients with myopathy, there is evidence that various forms of exercise therapy are 
beneficial for numerous endpoints, including strength, fatigue, and quality of life. Aerobic 
endurance (Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance training and detraining in 
mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2006 Dec;129(Pt12):3391–3401), and resistance (Murphy JL, 
Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. 
Brain. 2008 Nov;131(Pt 11):2832–2840) training programs have been studied. Exercise therapy may simply 
reverse the deconditioning, which is a common feature of many muscle diseases, or it is possible 
the exercise affects the underlying pathology, or a combination of these. 
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CINICAL EVALUTATION OF METABOLIC MYOPATHIES 
The most important component of evaluating patients with a suspected myopathy is obtaining a 
comprehensive medical history. Because many myopathies are inherited, obtaining a thorough 
family history is of tremendous relevance in making a correct diagnosis. A detailed family tree 
should be completed to evaluate for evidence of autosomal dominant, autosomal recessive, and X-
linked patterns of transmission.  
Symptoms of muscle disease can be divided into negative complaints, such as exercise intolerance, 
fatigue, muscle atrophy and weakness, and positive complaints, such as contractures, cramps, 
myalgias, muscle stiffness, and myoglobinuria. Weakness is by far the most common negative 
symptom reported by patients with muscle disease. When the upper extremities are involved, 
patients notice trouble brushing their teeth, combing their hair, or lifting objects overhead. If the 
weakness involves the lower extremities, patients will complain of difficulty arising from a low 
chair or toilet, getting up from a squatted position, or climbing stairs. These symptoms in the arms 
and legs indicate proximal muscle weakness, which is probably the most common distribution of 
weakness in a myopathic disorder. Fatigue is a much less useful negative symptom because it may 
be a result of patients’ overall health, cardiopulmonary status and level of conditioning. However, it 
is important to define the intensity and duration of exercise that provokes the fatigue. Myalgias may 
be episodic and may be associated to muscle cramps. Myoglobinuria is caused by the excessive 
release of myoglobin from muscle during periods of rapid muscle destruction (rhabdomyolysis) and 
is a relatively uncommon manifestation of muscle disease. Severe myoglobinuria can result in renal 
failure caused by acute tubular necrosis. It is obviously important to determine the onset, duration, 
and evolution of these symptoms and signs. Moreover, a history of precipitating factors that might 
trigger or exacerbate symptoms of weakness or myotonia should be explored. Involvement of 
organs or tissues other than muscle may also provide helpful clues in making the appropriate 
diagnosis. For example, respiratory failure may be the presenting symptom of acid maltase 
deficiency. 
The laboratory investigation should include blood and urine tests, the forearm ischemic exercise 
test, electromyography, muscle biopsy, and molecular studies. 
Blood and Urine Testing. Abnormal levels of specific compounds in the blood or urine, either alone 
or in combination, may help diagnose or suggest a specific type of metabolic abnormality. Tests 
primarily include CK, lactate, pyruvate, blood glucose and myoglobin. The CK level should be 
tested at rest and also during episodes of acute reversible muscle dysfunction with or without 
myoglobinuria. In patients with glycogen defects the CK level may be elevated at rest, particularly 
in patients with static features. By comparison, in other patients the CK can be normal between 
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acute episodes. Blood lactate and pyruvate may be elevated in patients with mitochondrial 
myopathies; the lactate/pyruvate ratio is useful in determining the site of enzymatic block in the 
pathways of mitochondrial metabolism. The determination of serum and urine myoglobin is 
important in patients with suspected rhabdomyolysis. Patients with acute myoglobinuria may have 
concurrent elevation of serum creatinine, potassium, phosphate, uric acid (myogenic 
hyperuricemia), or even serum amino acids (particularly taurine). In the patient with a suspected 
lipid metabolism defect, levels of plasma total and free carnitine, serum free fatty acids and ketones, 
serum acylcarnitines, urine acylglycines, and organic acids should be determined. The testing 
should preferably be performed during episodes of acute catabolic crises before glucose 
administration or during periods of fasting because normal values may be observed when the 
patient is metabolically stable and not fasting. 
Electromyography.  In patients with a fixed weakness, electromyography can be useful in excluding 
a neuropathic process and providing evidence for a myopathic condition. Myotonic discharges are 
evident in patients with myophosphorylase or acid maltase enzyme deficiency. In patients with 
excessive fatigability, repetitive nerve stimulation could be instrumental in excluding a defect in 
neuromuscular transmission (Griggs R, Mendell J, Miller R. Metabolic myopathies. In: Griggs R, Mendell J, Miller R, eds. Evaluation 
and treatment of myopathies. Philadelphia: F.A. Davis, 1995:247-93). 
Six minute walking test. The six minute walking test (6MWT) is a useful measure of functional 
capacity, targeted at people with reduce exercise tolerance. It has been widely used for measuring 
the response to therapeutic interventions for patient management and research in patients with 
moderate-to-severe cardiopulmonary. The 6MWT is a test of relatively low complexity that 
measures the distance that a patient can quickly walk in a period of 6 min, referred to as the 6-min 
walk distance (6MWD). A change in 6MWD is usually reported as an absolute value in meters or 
feet. Alternatives are percentage change or change in percentage predicted. Besides it has emerged 
as the most commonly used test for the objective assessment of functional exercise capacity, 
statistically significant differences in groups from clinical trials are usually much smaller than a 
clinically important change in an individual patient.  
Forearm Ischemic Exercise Test.  If the clinical evaluation and laboratory findings suggest an 
enzymatic defect in the nonlysosomal glycogenolytic pathway and also in glycolysis, then the 
forearm ischemic exercise test should be performed. This test can be useful in assessing all patients 
with exercise intolerance (DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Engel A, Banker B, eds. Myology. New York: 
McGraw-Hill, 1994:1554-76), although its use in younger children is limited. A needle should be placed in a 
superficial antecubital vein, and resting blood samples should be obtained for determination of 
serum lactate, pyruvate, CK, and ammonia levels. The blood pressure cuff should be inflated to a 
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pressure level above the systolic pressure, and the patient should be asked to perform one per 
second hand grips at least 75% of his maximum voluntary hand grip. If an acute cramp develops, 
the cuff should be immediately deflated. Some recommend that the test be performed without the 
blood pressure cuff in place; others inflate the cuff at a value intermediate between the systolic and 
diastolic blood pressures. If the patient tolerates the test and exercises adequately, blood samples 
should be obtained at intervals of 1, 2, 3, 5, and 10 minutes (after removal of the blood pressure 
cuff), for determination of the serum lactate, pyruvate, and ammonia levels; a single sample should 
be obtained for CK. Basal blood lactate values can be increased in patients with mitochondrial 
disorders or glycogenosis type 1 (Livingstone C, Chinnery PF, Turnbull DM (2001) The ischaemic lactate-ammonia test. Ann Clin 
Biochem 38:304–310). In normal individuals after a good effort a threefold to fivefold rise in lactate is 
evident within the first 1-3 minutes. The rise in serum ammonia is similar but somewhat slower and 
more gradual, reaching a peak at 3-4 minutes. When the glycogenolytic or glycolytic pathway is 
blocked, as McArdle disease, the ischemic forearm exercise test reveals failed lactate production 
with normal or exaggerated ammonia concentration increase (Sinkeler SP, Wevers RA, Joosten EM, Binkhorst RA, 
Oei LT, Van’t Hof MA, De Haan AF (1986) Improvement of screening in exertional myalgia with standardized ischemic forearm test. Muscle Nerve 
9:731–737). Patients with myophosphorylase deficiency may exhibit an abnormally high rise in 
ammonia.  
Aerobic exercise test. Exercise testing can be a useful ancillary tool, especially to better characterize 
muscle fatigue and exercise intolerance referred by the patients. The main exercise tests used for 
diagnostic purposes in patients are performed with lactate determination during cycle or treadmill 
ergometry (Schmidt M, Kunkel M, Schuff-Werner P, Naumann M, Reichmann H, Reimers CD (1997) Standardised aerobic treadmill ergometry 
in healthy subjects and patients with mitochondrial and non-mitochondrial myopathies. Nervenarzt 68:831–835). No unique standardized 
protocols, at the moment, have been established. The aerobic exercise test can be performed 
following an incremental cycle test (Siciliano G, Rossi B, Manca L, Angelini C, Tessa A, Vergani L, Martinuzzi A, Muratorio A 
(1996) Residual muscle cytochrome c oxidase activity accounts for submaximal exercise lactate threshold in chronic progressive external 
ophthalmoplegia. Muscle Nerve 19:342–349) or a cycle test with a fixed constant absolute workload (Vissing J, Haller 
RG. A diagnostic cycle test for McArdle’s disease. Ann Neurol 54: 539–542, 2003). In the skeletal muscle of patients with 
metabolic myopathies, a limited ability to increase the extraction of O2 from blood relative to the 
increase in O2 delivery by the circulation during exercise has been described (Grassi B, Marzorati M, 
Lanfranconi F, Ferri A, Longaretti M, Stucchi A, Vago P, Marconi C, Morandi L. Impaired oxygen extraction in metabolic myopathies: detection and 
quantification by near-infrared spectroscopy. Muscle Nerve 35: 510–520, 2007). 
Muscle Biopsy. Given the impracticality of testing muscle biopsy tissue for all known metabolic 
defects, the initial clinical and laboratory assessment helps target the immunohistochemical and 
biochemical testing of the muscle tissue. The microscopic examination of the muscle sample 
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should include electron microscopy and immunohistochemical staining using various antibodies 
(e.g., phosphorylase, phosphofructokinase, cytochrome-c  oxidase, and myoadenylate deaminase) if 
deficiencies of the respective enzymes are diagnostic possibilities. Microscopic examination will 
determine the presence or absence of glycogen or lipid storage or ragged–red fibers, such as in 
mitochondrial myopathies. Because these evaluations will be normal in a number of metabolic 
defects, additional biochemical evaluation of the muscle tissue may be pursued; the evaluation 
should focus on specific possible biochemical defects (e.g., assays of glycogenolytic/glycolytic 
enzymes, electron transfer chain complexes, and FAO enzymes) on the basis of the results of the 
preliminary noninvasive evaluations.  
Molecular Studies.  Specific defects can be characterized at the molecular level either by Western 
blotting or by molecular analysis of specific mutations. Western blotting can be used to differentiate 
between a kinetic deficiency and a defect in the production of the relevant enzyme. The 
identification of specific mutations (e.g., phosphorylase gene and mitochondrial genome mutations) 
can be used to precisely and rapidly detect specific defects and also to perform presymptomatic, 
prenatal, and carrier detection. 
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FUNCTIONAL EVALUATION OF OXIDATIVE METABOLISM 
Most activities of daily living, such as rising from a chair, opening a jar, lifting a box, or walking at 
a slow pace, require only a modest amount of muscle strength or endurance, and do not involve 
significant demands on the respiratory or cardiovascular systems. However, vigorous aerobic 
exercises, such as running or sustained stair climbing, require tight integration of multiple systems 
in the body including the respiratory, cardiovascular, and neuromuscular systems. During physical 
exercise, adequate interactions among these systems are required to transport an adequate amount 
of oxygen and nutrients to the exercising muscles as well as to remove the metabolically produced 
carbon dioxide from the exercising muscles, to maintain homeostasis. Accordingly, each of these 
systems has important functions. The respiratory system, for example, is a ventilatory pump, 
moving oxygen from the atmosphere to the alveoli and carbon dioxide from the alveoli to the 
atmosphere. It must also provide an effective means of exchanging oxygen and carbon dioxide 
across the thin alveolar walls. The heart is responsible for pumping oxygenated blood to the 
exercising muscles as well as returning oxygen-poor and carbon dioxide-rich blood to the gas-
exchanging surfaces of the lungs. Finally, the muscles must extract oxygen from the blood, generate 
adenosine triphosphate (ATP) in the mitochondria, and contract with force sufficient to support the 
intended activity. 
 
Figure 8. The pathway for oxygen (from Exercise and Sport Science Review 2007) 
The systems do not work independently but rather in a highly coordinated manner. The most 
significant interdependence is the delivery of oxygen to the working muscles. The lungs must 
efficiently oxygenate blood returning from the venous system, and the left heart must then distribute 
this oxygenated blood to skeletal, cardiac, and respiratory muscles in proportion to the amount of 
work being done by the individual muscles. All of this coordination must occur in proportion to the 
 27 
amount of work being performed, whether it is mild, moderate, or extreme exercise. If we define 
VO2max as the maximal capacity of the pulmonary and cardiovascular system to take up and 
transport oxygen to the exercising muscles and of the exercising muscles to extract and utilize 
oxygen from the blood during progressive exercise, VO2max is the product of the maximal cardiac 
output and the maximal arteriovenous oxygen difference (Fick equation, see below). Pathology in 
any of the important systems noted above can lead to limitations in an individual’s exercise 
tolerance (i.e. VO2max). In patients with cardiomyopathy, for example, delivery of oxygen to the 
exercising muscles is insufficient to support mitochondrial ATP generation and, as a result, muscle 
contraction. Similarly, in patients with severe chronic obstructive pulmonary disease (COPD), 
altered respiratory system mechanics impair ventilation and the patient cannot eliminate carbon 
dioxide (CO2) being produced in the exercising muscles.  
Patients often discount the importance of loss of exercise tolerance as a significant symptom and the 
clinical exams usually performed are not able to explain the source of the problem and further 
evaluation is necessary. One of the studies that can be used to determine the etiology of unexplained 
dyspnea on exertion is the cardiopulmonary exercise test (CPET). Cardiopulmonary exercise testing 
provides information regarding the body's response to exercise. Cardiovascular performance and 
ventilatory criteria are assessed during a progressive-intensity exercise stimulus to provide an 
integrated analysis of the physiologic responses required by the cardiovascular and respiratory 
systems to meet the metabolic demands of the skeletal muscle (i.e., the primary consumers of 
oxygen during exercise).This test requires 20–30 minutes to perform using either a treadmill or a 
cycle ergometer, during which time the patient’s heart rate, oxygen saturation, and 
electrocardiogram (ECG) are monitored continuously, while blood pressure is measured 
intermittently. The individual wears a tight fitting mask to allow collection of all exhaled gases to 
measure minute ventilation, oxygen uptake, and carbon dioxide production. In some cases, blood 
gases are also measured using a radial artery catheter or intermittent arterial punctures.  
Assessing Overall Exercise Capacity: Maximum Oxygen Consumption. As described above, the 
ability to perform sustained, vigorous exercise depends on the participation of multiple systems 
including the respiratory, cardiovascular, and neuromuscular systems. In particular, several 
important tasks must be accomplished by these and other systems to support physical activity, 
including: ventilation to deliver oxygen to the alveoli and eliminate carbon dioxide; gas exchange to 
move oxygen from the alveoli to the blood and carbon dioxide from the blood to the alveoli; 
maintenance of hemoglobin stores to bind and carry oxygen to the tissues; delivery of oxygenated 
blood to the exercising tissues and carbon dioxide to the lungs; extraction of oxygen by the muscle 
mitochondria where ATP is generated to support muscle contraction. 
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To assess an individual’s capacity to perform all of these tasks and conduct sustained, vigorous 
exercise, one of the most useful parameters is the maximum oxygen consumption (VO2max) a 
parameter which describes how much oxygen is being used by the tissues per minute. To 
understand the value of this parameter in assessing overall exercise capacity, we can look at the 
determinants of VO2 using the Fick equation: 
 
where Q indicates the cardiac output, CaO2 indicates arterial oxygen content, and CvO2 indicates 
the mixed venous oxygen content. Rearranging this equation we see that: 
 
This tells us that oxygen consumption is a function of cardiac output and the arteriovenous oxygen 
content difference. 
Recall that: 
 
and 
 
where Hb = hemoglobin concentration, PaO2= partial pressure of oxygen in arterial blood, PvO2= 
partial pressure of oxygen in mixed venous blood, SaO2= arterial oxygen saturation, and SvO2= 
mixed venous oxygen saturation. Oxygen consumption is therefore dependent on the hemoglobin 
concentration, the arterial partial pressure and saturation of oxygen (reflecting the adequacy of the 
ventilatory pump and gas exchange), and the mixed venous saturation and partial pressure of 
oxygen (reflecting the ability of the tissues to extract and utilize oxygen). As a result, VO2max 
gives us information about many of the systems that are necessary to generate sustained, vigorous 
exercise; the higher the VO2max, the more effective all of these systems are at performing their 
tasks and the greater the person’s exercise capacity. Maximum oxygen consumption will vary from 
individual to individual. Whereas the VO2max for an average 30-year-old person might be 35–40 
ml/kg/minute, an elite cyclist or cross-country skier might have a VO2max of 85 ml/kg/minute. 
Patients with a cardiomyopathy, on the other hand, may have a VO2max as low as 15 ml/kg/minute 
or less, severely limiting the capacity to perform normal activities of daily living. Maximum oxygen 
consumption declines with age, although that decline may be substantially delayed in physically 
active subjects. 
Anaerobic or Ventilatory Threshold. As described before, during incremental exercise ventilation 
increases to deliver oxygen to the alveoli and eliminate carbon dioxide. The ventilatory threshold 
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(VT) is the point in which the linear increase of ventilation in relation to workload changes its 
slope. The VT is related to the point at which anaerobic metabolism increases in exercising muscles 
to sustain work when aerobic metabolic capacity can no longer meet the physiologic demands, and 
the body shifts to anaerobic metabolism as an additional source of energy. The VT is a noninvasive, 
reliable, and reproducible diagnostic/prognostic marker that is based on ventilatory dynamics as 
exercise intensity progresses. The VT usually occurs at approximately 45% to 65% of peak VO2  in 
healthy untrained subjects, and at a relatively lower percentage of peak VO2 among subjects with a 
reduced exercise capacity. A key utility of VT is that it provides information at a submaximal level 
of exercise intensity (i.e., it does not require a physiologically maximal exercise effort). Thus, the 
VT is useful as a parameter on which to base an exercise prescription for patients with a reduced 
maximal exercise performance (i.e. exercise intolerance). 
VO2/Work Rate Relationship. In general, there is a linear relationship between increasing VO2 and 
the work rate (watts) achieved. The slope of this relationship reflects the ability of exercising 
muscle to extract O2 and to aerobically generate ATP. In general, a reduction (10 mL/min/w) 
throughout the exercise test or an acute flattening at a given point during exercise in the 
ΔVO2/ΔWR relationship suggests the possibility of a problem in O2 transport (Wasserman K, Hansen JE, Sue 
DY, et al. Normal Values. In: Weinberg R, ed. Principles of Exercise Testing and Interpretation. Philadelphia, PA: Lippincott, Williams and Wilkins, 
2005:160–182). General reductions may be seen in heart and lung disease, and disease in peripheral 
arterial function and/or mitochondrial myopathy, in which there are alterations in the cellular 
pathways involved in O2 utilization. Furthermore, a pattern of initial rise of the ΔVO2/ΔWR during 
exercise followed by abrupt flattening may reflect the onset of ischemia-induced left ventricular 
(LV) dysfunction in patients with coronary heart disease (CHD). Because consistent and accurate 
quantification of workload during treadmill testing is complicated by underlying variability during 
treadmill protocols (eg, body weight and handrail holding), assessment of the ΔVO2/ΔWR 
relationship is typically confined to exercise tests using a cycle ergometer. 
 
NEAR-INFRARED-SPECTROSCOPY 
Starting with the pioneering work of Jobsis over 25 years ago (1977), noninvasive near-infrared 
(NIR) spectroscopy (NIRS) has been used first to investigate experimentally and clinically brain 
oxygenation, and later muscle oxidative metabolism in pathophysiology. The physical principles of 
NIRS is based on the absorption of light NIR by hemoglobin (Hb) in small arterioles, capillaries 
and venules. Briefly, NIR light (700–1000 nm) penetrates skin, subcutaneous fat/skull, and 
underlying muscle/brain, and is either absorbed or scattered within the tissue (Fig. 9).  
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Figure 9. Schematic representation of NIR light traveling through the muscle 
Based on the Beer-Lambert Law, photons migrate successfully through tissue regions with the least 
absorbance. In the smallest vessels, minimal light absorption allows for multiple complete passage 
of photons along their path through tissue and therefore changes in chromophore concentrations can 
be detected from the light absorption. In contrast, light emitted into larger vessels (arteries and 
veins) is almost completely absorbed since the molar quantity of blood is so comparatively large. 
The relatively high attenuation of NIR light in tissue is due to: (a) O2-dependent absorption from 
chromophores of variable concentration, i.e., hemoglobin (Hb), myoglobin (Mb) (in the muscle 
only), and cytochrome oxidase; (b) absorption from chromophores of fixed concentration (skin 
melanine); or (c) light scattering. Thus, the oxygen saturation of the investigated tissue can be 
estimated. The parameters commonly derived from NIRS studies in humans are: deoxygenated Hb 
and myoglobin (Mb) concentrations, oxygenated Hb and Mb concentrations,  and the sum of the 
two variables which is related to changes in the total Hb volume in the muscle region of interest. 
Moreover, the ratio of oxyhemoglobin (HbO2) to total hemoglobin (THb) can be calculated to 
estimate an index of changes in tissue O2 saturation relative to rest. This parameter indicates the 
balance between O2  delivery and tissue O2 consumption. The brain/muscle volume measured by 
the different NIRS approaches is still controversial. However, it is generally accepted that, for a 
source-detector separation of 3 cm, the region of maximum brain/muscle sensitivity will be found 
between the source and detector fiber tip location, and roughly 1.5 cm below the surface of the skin, 
though a banana-shaped region of sensitivity extends both above and below this depth (Strangman 
et al., 2002a).  
Several types of NIRS spectrophotometry devices have been developed varying in sophistication 
and ease of application, algorithms used and number of wavelengths employed (Ferrari M, Binzoni T, 
Quaresima V. Oxidative metabolism in muscle. Phil Trans R Soc Lond B 1997: 352: 677–683). The most versatile and widely used 
devices are continuous wave spectrometers which do not allow quantitative measures of absolute 
concentrations of the chromophores, but instead provide concentration changes deviating from a 
baseline value (i.e. rest) during variations in O2  availability and utilization. 
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Today, NIRS is extensively utilized to study circulatory and muscle metabolic pathologies in 
several situations. Distinct abnormalities in tissue oxygenation have been detected with NIRS in 
patients with peripheral vascular disease (McCully KK, Halber C, Posner JD. Exercise-induced changes in oxygen saturation in 
the calf muscles of elderly subjects with peripheral vascular disease. J Gerontol 1994: 49: B128–B134). Pronounced muscle O2 
desaturation during exercise and delayed recovery after exercise have been observed in heart failure 
patients with impaired cardiac output and muscle blood flow (Hanada A, Okita K, Yonezawa K, 
Ohtsubo M, Kohya T, Murakami T, Nishijima H, Tamura M, Kitabatake A. Dissociation between muscle metabolism and oxygen kinetics during 
recovery from exercise in patients with chronic heart failure. Heart 2000: 83:161–166). Furthermore, abnormalities in muscle 
oxidative metabolism in individuals with mitochondrial myopathies (Grassi B, Marzorati M, Lanfranconi F, Ferri 
A, Longaretti M, Stucchi A, Vago P, Marconi C, Morandi L. Impaired oxygen extraction in metabolic myopathies: detection and quantification by 
near-infrared spectroscopy. Muscle Nerve 35: 510–520, 2007) have been detected with NIRS. These observations 
suggest that NIRS may have a diagnostic role in assessing the presence and extent of both 
circulatory and metabolic disorders. 
 
VO2 KINETICS  
The study of VO2 kinetics starts in the nineteenth-century thanks to the English Nobel laureate, 
Archibald Vivian Hill, who studied the dynamics of metabolic processes in muscles isolated from 
small animals and used these data to develop his ideas about energetics within human athletes. The 
term ‘kinetics’ indicates ‘the study of the action of force in producing or changing something’ and, 
therefore,  the term “VO2 kinetics” is utilized to identify the study of the physiological mechanisms 
responsible for the dynamic VO2 response to exercise and its subsequent recovery.  
Other than when sleeping or being completely immobile, humans are rarely in a metabolic steady 
state. At the onset of movement or dynamic exercise such as cycling or running, the energetic 
requirements of the contracting muscles increase immediately with the first contraction in what has 
been termed a ‘square-wave’ fashion. However, as demonstrated in Figure 10, neither the increase 
in pulmonary nor muscle VO2 have ‘square-wave’ response profiles.  
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Figure 10. Upper: Actual breath-by-breath alveolar VO2 response across the transient from 
unloaded cycling (0W) to a moderate work rate  for a representative subject (data from Grassi et al., 
1996). Lower: Increase in muscle VO2 at the onset of muscle contractions (time 0) in rat 
spinotrapezius measured directly from capillary red blood cell flux and microvascular O2 pressures 
(Behnke et al., 2002).  
 
The response demonstrates considerable inertia and, depending on the health or fitness of the 
individual and the exercise intensity, may take from 2 to 15 or more min to achieve the steady-state 
values (Figures 1.8 and 1.9). More specifically, at the onset of constant workrate exercise, there is 
an early rapid increaseof VO2 that is typically initiated within the first breath (Phase I, Fig. 10). 
This initial increase in Phase I is followed by a rapid exponential increase in  (Phase II) with a time 
constant or τ of some 20–45s (healthy individuals) that drives  to the actual, or towards the initially 
anticipated, steady-state value (Phase III) within 3 minutes. Phase I represents the O2 exchange 
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associated with the initial elevation of cardiac output and thus pulmonary blood flow. Phase II 
reflects the arrival at the lung of venous blood draining the exercising muscles. The pulmonary  
kinetics in Phase II therefore largely reflect the kinetics of O2 consumption in the exercising 
muscles, although there is a temporal lag between events at the muscle and those recorded at the 
lung. For moderate intensity exercise, the onset of Phase III corresponds to the point at which 
cardiac output plateaus and venous O2 content reaches its nadir. At higher exercise intensities, the 
attainment of a steady state might be delayed or absent (Fig. 11). 
 
Figure 11. Schematic representation of the VO2 response to constant work-rate exercise in the 
moderate (below lactate threshold), heavy (above the lactate threshold) and severe (above the 
asymptote of the power-time relationship for high-intensity exercise, critical power) exercise 
domains. 
 
In the transition from rest or unloaded exercise to a work rate with a  requirement below the 
anaerobic threshold, the vertical distance between the actual  at a given moment and that required in 
the steady state represents the energy requirement that must be met from energy stores within the 
muscle. These stores consist principally of energy released through phosphocreatine hydrolysis and 
anaerobic glycolysis, with a small contribution from O2 stores (myoglobin, venous blood). The 
total O2 equivalent of that amount of energy is termed the O2 deficit. Thus, for a given VO2 the 
faster the  response (smaller τ), the smaller is the O2 deficit that will be incurred. In contrast, 
extremely unfit or unhealthy individuals will have a very slow response (larger τ) and will incur a 
high O2 deficit and thus a greater degree of intracellular perturbation (increased lactic acid, 
decreased PCr). Slow  kinetics mandate a greater depletion of intramuscular [PCr] and a greater rate 
of glycogenolysis leading to greater accumulation of lactate and protons and a greater utilization of 
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the finite intramuscular glycogen reserves, all factors which predispose to a reduced exercise 
tolerance.  
Model characterization of  kinetics. It has been established that the VO2 response to constant 
workrate exercise in Phase II is essentially exponential. This exponential nature of the  response can 
be described with the following equation: 
 
where (t) is the  at any point in time, (b) is the baseline before the commencement of the step 
transition to a higher work rate, A is the steady-state amplitude of the VO2 response, and (1–e 
−(t−TD)/τ) is the exponential function describing the rate at which VO2 is rising towards the steady-
state amplitude. In this exponential function, t is time, TD is the time delay before the start of the 
exponential term and τ is the time constant, i.e. the time required for the attainment of 63% of the 
total amplitude. To note, the exponential increase of pulmonary VO2 following the onset of 
muscular exercise is essentially a ‘mirror image’ of the exponential reduction of intramuscular 
[PCr], once the ‘muscle to mouth’ transport delay time has been accounted for (Rossiter, H.B., Ward, S.A., 
Doyle, V.L., Howe, F.A., Griffiths, J.R. and Whipp, B.J. (1999). Inferences from pulmonary O2 uptake with respect to intramuscular 
[phosphocreatine] kinetics during moderate exercise in humans. Journal of Physiology, 518). This strongly suggests that muscle  
kinetics are principally under feedback control from one or more of the products of high-energy 
phosphate splitting. 
It is important to remember that, in the non-steady state, the relationship between muscle and 
pulmonary  is distorted by at least three factors: the transit delay between the muscle and the lung; 
muscle and venous O2 stores; and the kinetics of cardiac output (a given a-vO2 difference at the 
muscle will be associated with a faster blood flow when it reaches the lung 5–20s later). However, 
direct experimental measurements confirm that the Phase II pulmonary  kinetics provide a close 
approximation of the kinetics (amplitude and time constant) of increased muscle O2 consumption 
following the onset of exercise (Grassi, B., Poole, D.C., Richardson, R.S., Knight, D.R., Erickson, B.K. and Wagner, P.D. (1996). 
Muscle O2 uptake kinetics in humans: implications for metabolic control. Journal of Applied Physiology, 80). For heavy and severe 
intensity exercise, an additional exponential term is required for satisfactory fitting of the  on-
response following the completion of Phase I: 
 
where Ap and As are the amplitudes of the  primary and slow components, respectively, TDp and 
TDS are the independent time delays before the commencement of the primary and slow 
components, respectively, and τp and τs are the time constants for the primary and slow 
components, respectively. It has been demonstrated that the kinetics in heavy and severe exercise 
are better fit with two exponential terms than with a single exponential term following the 
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completion of Phase I. This suggests that the slow component does not start at exercise onset but 
‘appear’ later in exercise. The time at which the slow component begins to develop depends on the 
exercise intensity (it begins earlier at higher work rates within the heavy and severe domains) but is 
normally at ~2min following the onset of exercise (Burnley, M., Jones, A.M., Carter, H. and Doust, J.H. (2000). Effects of 
prior heavy exercise on phase II pulmonary oxygen uptake kinetics during heavy exercise. Journal of Applied Physiology, 89, 1387–96).   
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ABSTRACT 
Purpose: Enzyme replacement therapy (ERT) has recently became available for Pompe’s disease. 
Data on the effects of ERT on physiological variables related to exercise tolerance have never been 
published. Methods: Pulmonary gas exchange, cardiac output (by impedance cardiography), vastus 
lateralis muscle O2 extraction (by near-infrared spectroscopy) were determined during cycle 
ergometer exercise in a 50-year-old patient BEFORE and after 1, 12 and 24 months of ERT. 
Results: At the same constant-workload submaximal exercise, rates of self-perceived exertion and 
values of respiratory exchange ratio, pulmonary ventilation and heart rate were lower during ERT 
vs. BEFORE, suggesting an increased exercise tolerance. Peak oxygen uptake ( O2peak) increased 
by ~35% from BEFORE (0.64 L/min, or 11.4 ml/kg/min) to 1 month (0.88 L/min, or 15.7 
ml/kg/min) of treatment, and did not significantly change thereafter. Also peak cardiac output 
significantly increased during ERT, whereas peak skeletal muscle fractional O2 extraction was 
unchanged compared to BEFORE. Conclusions: Improvements of peak exercise capacity and 
exercise tolerance at submaximal workloads were  observed in a patient with Pompe’s disease after 
1 month of ERT, with no further changes during the ensuing treatment period (up to 24 months).  
 
Keywords: glycogen storage disease type II; cycle ergometer exercise; cardiac output; O2 uptake; 
near-infrared spectroscopy. 
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INTRODUCTION 
 
Paragraph number 1. Pompe’s disease, also known as glycogenosis type II or acid maltase 
deficiency, is an inherited myopathy caused by the deficiency of lysosomal acid a-glucosidase 
(GAA) or acid maltase. The enzyme catalyzes the hydrolysis of a-1,4 and a-1,6 links of glycogen 
and its deficiency leads to intra-lysosomal accumulation of glycogen. The disease presents as a 
continuum of clinical phenotype, varying according to age at onset, organ involvement and severity 
of progression. The severe infantile disease is characterized by generalized muscle weakness, 
hypertrophic cardiomyopathy and an invariably fatal outcome by 1 year of age. Patients with late-
onset Pompe’s disease present with progressive muscle weakness that can also affect pulmonary 
function. A considerable number of patients become wheelchair dependent and may require assisted 
ventilation later in life (8). An inverse correlation is usually observed between the amount of 
residual GAA activity and disease severity, and in general the symptoms do not emerge until the 
GAA activity remains above 30% of average normal activity (23). According to Nascimbene et al. 
(12) patients with Pompe’s disease would have a predominant expression of inactive forms of acid 
a-glucosidase protein and severely reduced or absent levels of mature forms, and disease severity 
would be primarily determined by the amount of functional protein. 
Paragraph number 2. Until recently, no effective therapy for Pompe’s disease was available, even 
if positive effects have been reported with a combination of high-protein and low-carbohydrate 
nutrition and exercise (18). Enzyme replacement therapy (ERT) with recombinant human a-
glucosidase became available in 2000 (20), and currently a number of studies have been published 
on the efficacy and safety of ERT in Pompe’s disease. Clinical studies in infants have shown that 
ERT led to improvement in skeletal and cardiac muscle function and to increased survival in many 
patients (10). As far as the effects of this treatment in older children and adults is concerned, data 
were available only for a limited number of patients (2,16,19,25). A few months ago the first 
randomized double-bind, placebo-controlled trial on 90 patients with late-onset Pompe’s disease 
was published (22). Treatment with a-glucosidase was associated with improved walking distance 
and stabilization of pulmonary function over an 18-month period. To our knowledge, data on the 
effects of this therapy on physiological variables related to exercise tolerance have never been 
published. This would be relevant, since in patients with Pompe’s disease the reduced exercise 
tolerance significantly affects the patients’ clinical picture and quality of life. 
Paragraph number 3. We report a 24-month follow-up of an adult patient who underwent ERT. In 
particular, data related to cardiovascular and metabolic responses to exercise and respiratory 
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function are provided. All measurements were non-invasive, so they could be easily repeated as a 
function of time. 
 
PATIENT AND METHODS 
 
Paragraph number 4. The patient, a 50 year-old female (height 162 cm, body mass 57 kg and 
body mass index 21.7 kg·m-2), was first investigated at the age of 38 years because of muscle 
weakness and easy fatigability. Muscle biopsy revealed few myopathic changes and PAS-positive 
and phosphatase-positive intracytoplasmic vacuoles. Pompe’s disease was confirmed by the 
observation of a reduced GAA activity in muscle tissue. During the follow-up period, a slowly 
progressive decline in muscle strength, mainly involving pelvic girdle and proximal lower limb 
muscles was observed. At the age of 48 years, the patient was still able to walk and work but 
complained of difficulty in climbing stairs and standing up from a chair and also experienced 
feeding and swallowing difficulties. A clinically significant cardiac involvement was excluded by 
electrocardiogram and echocardiogram. ERT with recombinant human a-glucosidase 
(MyozymeTM, Genzyme Corporation, Cambridge, Mass) was administered intravenously at a dose 
of 20 mg/kg every two weeks. Before treatment (BEFORE) and after 1, 12 and 24 months of ERT 
the patient was evaluated in our laboratory. The subject was fully informed of any risk and 
discomfort associated with the experiments before giving her written informed consent to 
participate to the study, which was approved by the local institutional ethics committees. All 
procedures were in accordance with the recommendations found in Declaration of Helsinki (2000) 
of the World Medical Association. 
Paragraph number 5. Assessment included evaluations of neuromuscular, pulmonary functions 
and exercise tolerance. Muscle strength was evaluated by manual muscle testing and graded 
according to the 5 point score Medical Research Council (MRC) scale (11). The following muscles 
were bilaterally tested: biceps, triceps, deltoid, digit flexors, arm intra-extrarotators, ilio-psoas, 
quadriceps, thigh abductors, adductors, flexors, and extensors, anterior and posterior tibialis, head 
flexors and extensors. The best side was considered. Total score ranged from 0 (“total paralysis”) to 
75 (“normal strength”). A Functional evaluation by the Walton scale (5) was also performed. Five 
functions were analyzed: gait (score range 1-7), climbing stairs (score range 1-7), getting up from a 
chair (score range 1-6), standing from the floor (score range 1-7), rising arms above the head (score 
range 1-6). Score 1 indicated a normally performed function, 6 or 7 impossibility to perform 
function.  
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Paragraph number 6. Since late-onset patients may present asymptomatic diaphragmatic 
weakness, revealed as a difference between pulmonary function variables between sitting and 
supine positions greater than 20% (“postural drop”) (21), forced vital capacity (FVC) and forced 
expiratory volume in one second (FEV1) were measured both in sitting and supine position. 
Paragraph number 7. Exercise tolerance was assessed on an electronically braked cycle ergometer 
(Corival, Lode, The Netherlands). After sitting for a few minutes at rest the patient performed at 15 
watts (W) for 6 minutes, thereafter the workload was increased by 10 W and the patient exercised 
for other 6 minutes or until voluntary exhaustion (defined by the inability to maintain the imposed 
pedalling frequency of 60 revolutions/min). At 12 and 24 months, after the exercise protocol 
described above and 20 minutes of recovery, the patient was able to perform an incremental 
exercise to voluntary exhaustion: 5 W/min increments were given after an initial step of 4 min at 15 
W. Levels of self-perceived exertion (RPE) were assessed using the validated Borg scale (1). For 
cardiovascular, gas exchange, and muscle oxygenation variables mean values were calculated 
during the last 30 seconds of each load. The highest values reached at exhaustion by the patient, 
during either the constant workload or the incremental exercise, were taken as “peak” values. 
Paragraph number 8. Pulmonary ventilation ( E, expressed in BTPS), O2 uptake ( O2), and 
CO2 output ( CO2), both expressed in STPD, were determined breath-by-breath by a metabolic 
cart (SensorMedics Vmax29c; The Netherlands). Arterial blood oxygen saturation (SaO2) was 
continuously monitored by pulse oximetry (Biox 3740, Pulse Oximeter, Ohmeda, Denver, CO) at 
the ear lobe. Heart rate was monitored from the electrocardiogram; stroke volume was estimated 
beat-by-beat by impedance cardiography (Physio Flow, Manatec, Paris, France). The accuracy of 
this device has been previously evaluated during incremental exercise in healthy subjects against 
the direct Fick method (15); in that study the correlation coefficient between the two methods was r 
= 0.946 (P<0.01), the mean difference was equal to -2.78 ± 12.33 (2 SD) %, and the accuracy of the 
impedance cardiography method was recognized to be “acceptable”. Cardiac output (CO) was 
calculated as HR·SV. The Fick equation was utilized to calculate systemic arteriovenous O2 
difference (Da- v O2). Oxygenation changes in vastus lateralis muscle were evaluated by near-
infrared spectroscopy (NIRS). A portable NIR single-distance continuous-wave near-infrared 
spectroscopy (HEO–100, Omron, Japan), was used. Concentration changes of oxygenated Hb+Mb 
(∆[oxy(Hb+Mb)]) and deoxygenated Hb+Mb (∆[deoxy(Hb+Mb)]), with respect to an initial value 
arbitrarily set equal to zero during the resting condition preceding the test, were calculated and 
expressed in arbitrary units (17). (∆[deoxy(Hb+Mb)]) was taken as an estimate of skeletal muscle 
O2 extraction because this variable, unlike (∆[oxy(Hb+Mb)]), is relatively insensitive to changes in 
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blood volume (3,6). A "physiological calibration" of the ∆[deoxy(Hb+Mb)] values was performed 
during a transient limb ischemia: data obtained during exercise were expressed as a percentage of 
the values determined by obtaining a maximal deoxygenation of muscle, after the exercise period, 
by pressure cuff inflation (at 300-350 mm Hg) carried out at the inguinal crease of the thigh for a 
few minutes until ∆[deoxy(Hb+Mb)] increase reached a plateau. Further details on the methods can 
be found in a previous paper by our group (7).  
 
RESULTS AND DISCUSSION 
 
Paragraph number 9. No side effects of therapy were observed. The patient reported a progressive 
subjective improvement of daily performance, and particularly less fatigability both at work and 
during the housekeeping activities. After 9 months of treatment she spontaneously started to 
perform 2-3 times per week short sessions (about 15 minutes) of exercise on a stationary bicycle. 
Paragraph number 10. Muscle strength total score varied from 57 before therapy to 60 after 12 
months and was unchanged at 24 months. A slight improvement was observed also in the Walton 
score, that changed from 20 (BEFORE) to 18 and 16 (after 12 and 24 months, respectively).  
Paragraph number 11. Before the start of treatment FVC was 95 and 72% of the predicted normal 
in sitting and supine position, respectively. FVC showed an improvement during ERT whereas 
FEV1 remained stable throughout the treatment period (see Figure 1). In individuals without 
restrictive respiratory impairment differences in pulmonary function variables from sitting to the 
supine positions usually vary by no more than 10% (13). Patients with late-onset Pompe’s disease, 
due to presence of marked diaphragmatic weakness, may present a “postural drop” (or an amount of 
volume lost between these positions greater than 20%). In our patient this feature was evident 
BEFORE and persisted during the 24 months of treatment.  
Paragraph number 12. The patient tolerated the exercise tasks relatively well and she never 
reported muscle cramps. ERT increased peak exercise capacity and exercise tolerance at 
submaximal workloads. The positive effects of ERT on exercise tolerance at submaximal workloads 
are highlighted by the data obtained during the constant workload exercise at 15 W (see Table 1). 
During ERT the patient referred progressively lower levels of self-perceived exertion, and achieved 
lower values of respiratory exchange ratio, pulmonary ventilation and heart rate. All these changes 
are considered, for the same absolute workload, classic signs of improved exercise tolerance. At 
BEFORE the patient was able to perform at 25 W for only 30 seconds, whereas at 12-month she 
completed the 6-min 25-W load. 
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Paragraph number 13. Although the incremental test could not be carried out in BEFORE, the 
“peak” values obtained during the incremental protocol after 12 and 24 months of ERT should be 
comparable to those obtained at exhaustion during the constant workrate tests. It is indeed well 
accepted that the values obtained at exhaustion during a constant load exercise lasting a few 
minutes are pretty similar to the values obtained at exhaustion during an incremental exercise (9); 
being determined at exhaustion, both values can be defined “peak” values of aerobic function. Peak 
values of O2, CO and  Da- v O2 are shown in the Figure 2. O2peak increased by ~35% from 
BEFORE (0.64 L/min, or 11.4 ml/kg/min) to 1 month (0.88 L/min, or 15.7 ml/kg/min) of ERT, and 
did not significantly change thereafter. O2peak values obtained during ERT correspond to ~4 
METs, or 4 times the resting energy expenditure (1 MET = 3.5 mlO2 · kg-1· min-1), and to about 
57% of the sex- and age-predicted peak value. The increase in O2peak was associated with a 
substantial increase in COpeak, that is in the peak capacity of cardiovascular O2 delivery. COpeak 
increased indeed from ~10 L/min in BEFORE to ~17-18 L/min during treatment; also for this 
variable the increase occurred early (within the first month) during ERT , with no significant further 
changes during the ensuing treatment period. Both HRpeak (which increased from 130 beats/min to 
147 and 148 beats/min at 1 and 24-month, respectively) and peak stroke volume (from about 77 mL 
at BEFORE to about 118 at 1-month and 133 mL at 12-month) contributed to the increased 
COpeak. Arterial blood oxygen saturation (SaO2) did not significantly decrease during any of the 
exercise protocols, suggesting a substantially normal cardiopulmonary function. 
Paragraph number 14. On the other hand, both the calculated systemic Da- v O2 peak and the 
measured (by NIRS) peak fractional O2 extraction by the vastus lateralis muscle were not 
significantly affected by ERT. The calculated peak Da- v O2peak during exercise did not change 
from the resting value (about 5-6 ml O2/100 ml), suggesting an impaired capacity to increase O2 
extraction. Also this finding was confirmed by NIRS data. In fact, during all exercise protocols, 
(∆[deoxy(Hb+Mb)] values, taken as an estimate of skeletal muscle fractional O2 extraction (for 
details see [7]), were substantially unchanged compared to those determined at rest.  
Paragraph number 15. As mentioned above, in the patient ERT improved exercise tolerance, as 
shown both by submaximal and peak data. The substantial increase in peak O2 was associated 
with a substantial increase in peak cardiac output, whereas peak fractional O2 extraction by skeletal 
muscles was not affected. It would be an oversimplification, however, to say that the lack of 
increase in skeletal muscle O2 extraction demonstrates a lack of improvement in skeletal muscle 
oxidative metabolism. In the presence of an increased peak O2 delivery, indeed, peak O2 uptake by 
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skeletal muscles (as estimated from pulmonary O2) significantly increased. The specific effects of 
ERT (and exercise training, see below) on oxidative metabolism within skeletal muscles of patients 
with Pompe’s disease should be evaluated by more specific investigations. Data from infants with 
Pompe’s disease indicate that cardiac muscle responds well to ERT, whereas the response of 
skeletal muscle is highly variable (24). Similarly, ERT treatment in the murine knock-out model of 
the disease reversed the pathology in cardiac muscle but has been less effective in skeletal muscle 
(4,14). Unfortunately, muscle biopsies were not performed in the present study.  
Paragraph number 16. As discussed above, the subjective improvement observed by the patient 
during the first few months of ERT induced her to spontaneously adopt a light exercise training 
protocol. Thus, it cannot be excluded that the beneficial effects described in the present study after 
the first few months of ERT can be attributed, at least in part, to the increased level of physical 
activity. It must be noted, however, that most of the beneficial effects (see e.g. those on O2peak) 
were already described after 1 month of ERT, that is well before the patient spontaneously started 
training (which occurred after about 9 months of ERT). It can be hypothesized that ERT and 
exercise training could have additive positive effects on these patients’ exercise tolerance and, 
ultimately, on their quality of life. We of course recognize that the present data were obtained only 
in one patient, and that they need to be confirmed in studies performed on a larger number of 
patients. 
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FIGURE 1. Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) 
measured before treatment (BEFORE) and after 1, 12 and 24 months of ERT both in sitting and 
supine position. 
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FIGURE 2. Peak values of oxygen uptake ( O2), cardiac output (CO) and systemic arteriovenous 
O2 difference (Da- v O2)  obtained before treatment (BEFORE) and after 1, 12 and 24 months of 
ERT. 
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ABSTRACT  
Enzyme replacement therapy (ERT) has recently became available for patients with glycogen 
storage disease type II (GSDII). Previous studies have demonstrated clinical efficacy of ERT, 
however, data on physiological variables related to exercise tolerance are scarce. Four GSDII late-
onset patients (45 ± 6 years) performed an incremental exercise on a cycle ergometer, up to 
voluntary exhaustion, before (BEFORE) and after 12 months of ERT (AFTER). Peak workload, 
oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis 
oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak 
workload and oxygen uptake values significantly increased during ERT (54 ± 30 vs. 63 ± 31 watt, 
and 17.2 ± 4.4 vs. 19.7 ± 3.5 ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, 
for both peak cardiac output (12.3 ± 5.3 vs. 14.8 ± 4.5 L/min) and the NIRS-determined peak 
skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a 
transient limb ischemia (30 ± 39 % vs. 38 ± 28 %), the observed increases were not statistically 
significant. Our findings suggest that in GSDII patients ERT is associated with a mild improvement 
of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group 
of patients. 
 
 
 
Keywords: glycogen storage disease type II; cardiac output; oxidative metabolism; near-infrared 
spectroscopy. 
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INTRODUCTION 
 
Glycogen storage disease type II (GSDII), also known as Pompe’s disease or acid maltase 
deficiency, is a rare, autosomal recessive, progressive neuromuscular disease caused by the 
deficiency of lysosomal acid a-glucosidase (GAA) or acid maltase. The enzyme catalyzes the 
hydrolysis of a-1,4 and a-1,6 links of glycogen and its deficiency leads to intra-lysosomal 
accumulation of glycogen. In patients with the classic infantile form, the deposition of glycogen in 
the heart, skeletal, and respiratory muscles causes severe cardiomyopathy, hypotonia, and 
respiratory failure, typically leading to death within the first year of age. In  late-onset GSDII 
patients  glycogen deposition is confined mainly to skeletal and respiratory muscles, causing 
progressive limb-girdle myopathy and respiratory insufficiency. A considerable number of patients 
become wheelchair dependent and may require assisted ventilation later in life. An inverse 
correlation is usually observed between the amount of residual GAA activity and disease severity, 
and in general the symptoms do not emerge until the GAA activity remains above 30% of average 
normal activity [1].  
Until recently, no effective therapy for GSDII patients was available, even if physical activity alone 
[2] or in parallel with an high-protein and low-carbohydrate dietary regime has been demonstrated 
to improve quality of life and motor function [3]. Enzyme replacement therapy (ERT) with 
recombinant human a-glucosidase became available in 2000 [4], and currently a number of studies 
have been published on the efficacy and safety of ERT in GSDII disease. Clinical studies in infants 
have shown that ERT led to improvement in skeletal and cardiac muscle function and to increased 
survival in many patients [5]. Few studies on the efficacy of this treatment in older children and 
adults have been published so far [6-9]. Overall these studies demonstrated that ERT is associated, 
over a 12-36-month period, with a stabilization of pulmonary function and with an improved 
exercise tolerance, as estimated by the 6-min walking test (6MWT), which has been demonstrated 
to be an appropriate outcome measure [10]. However, besides being intrinsically imprecise, the 
6MWT does not provide specific information on the function of the different organs and systems 
involved in exercise, or the mechanism of exercise limitation. Insights into these issues, together 
with a more precise quantification of the exercise intolerance, could derive from standard 
cardiopulmonary exercise testing, associated with measurements of pulmonary O2 uptake, cardiac 
and skeletal muscle functions carried out during incremental exercise up to voluntary exhaustion.      
In the present study we report a 12-month follow-up of four late-onset GSDII patients who 
underwent ERT. In particular, data related to cardiovascular and metabolic responses to exercise 
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and respiratory function are provided. All measurements were non-invasive, so they could be easily 
repeated as a function of time. 
 
MTERIALS AND METHODS 
Four late-onset GSDII patients (2 males and 2 females, 45 ± 6 years) were investigated. A clinically 
significant cardiac involvement was excluded by electrocardiogram and echocardiogram. ERT with 
recombinant human a-glucosidase (MyozymeTM, Genzyme Corporation, Cambridge, Mass) was 
administered intravenously at a dose of 20 mg/kg every two weeks. Before treatment (BEFORE) 
and after 12 months of ERT (AFTER) the patients were evaluated in our laboratory. The subject 
were fully informed of any risk and discomfort associated with the experiments before giving their 
written informed consent to participate to the study, which was approved by the local institutional 
ethics committees. All procedures were in accordance with the recommendations found in 
Declaration of Helsinki (2000) of the World Medical Association. 
The assessment included evaluations of pulmonary function and exercise tolerance. 
Pulmonary function variables, forced vital capacity (FVC) and forced expiratory volume in one 
second (FEV1), were measured with the patients in sitting position by a spirometer   
Exercise tolerance was assessed on an electronically braked cycle ergometer (Corival, Lode, The 
Netherlands). An incremental exercise was performed: after sitting for a few minutes at rest the 
patient performed at 15–30 W for 5 minutes, and thereafter the workload was increased by 5–10 W 
(according to the subject’s estimated level of physical fitness) every minute until voluntary 
exhaustion was reached. For cardiovascular, gas exchange, and muscle oxygenation variables mean 
values were calculated during the last 30 seconds of each load. The highest values reached by the 
patient were taken as “peak” values. 
Pulmonary ventilation ( E, expressed in BTPS), O2 uptake ( O2), and CO2 output ( CO2), both 
expressed in STPD, were determined breath-by-breath by a metabolic cart (SensorMedics 
Vmax29c; The Netherlands). Expiratory flow measurements were performed by a mass flow sensor 
(hot wire anemometer), calibrated before each experiment by a 3-liter syringe at three different flow 
rates. Tidal volume and 
.
VE were calculated by integration of the flow tracings recorded at the 
mouth of the subject. 
.
VO2 and 
.
VCO2 were determined by continuously monitoring partial pressures 
of oxygen (PO2) and carbon dioxide (PCO2) at the mouth throughout the respiratory cycle and from 
established mass balance equations, after alignment of the expiratory volume and expiratory gases 
tracings and A/D conversion. Calibration of O2 and CO2 analyzers was performed before each 
experiment by utilizing gas mixtures of known composition. Gas exchange ratio (R) was calculated 
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as 
.
VCO2/
.
VO2. Heart rate  (HR) was monitored from the electrocardiogram; stroke volume (SV) 
was estimated beat-by-beat by impedance cardiography (Physio Flow, Manatec, Paris, France). The 
accuracy of this device has been previously evaluated during incremental exercise in healthy 
subjects against the direct Fick method [11]. Cardiac output (CO) was calculated as HR·SV.  
Oxygenation changes in a superficial portion of the vastus lateralis muscle were evaluated by near-
infrared spectroscopy (NIRS). A portable NIR single-distance continuous-wave photometer (HEO–
100, Omron, Japan), was used. The instrument provides separate measurements of changes in 
deoxygenated Hb and Mb concentrations, as well as of oxygenated Hb and Mb concentrations, 
expressed in arbitrary units. Further details on the method can be found in a previous article by our 
group [12]. For a detailed discussion regarding advantages and limitations of NIRS measurements 
in skeletal muscle, the reader is referred to Ferrari et al. [13]. Concentration changes of 
deoxygenated Hb+Mb (D[deoxy(Hb+Mb)]), with respect to an initial value arbitrarily set equal to 
zero, were calculated and expressed in arbitrary units. D[deoxy(Hb+Mb)] was taken as an 
oxygenation index, since this variable is relatively insensitive to changes in blood volume [12]. 
D[deoxy(Hb+Mb)] data were expressed as a percentage of the values determined after the exercise 
by obtaining a maximal deoxygenation of the muscle, by pressure cuff inflation (at about 300 
mmHg) carried out at the inguinal crease of the thigh (subject in the sitting position on the 
cycloergometer), for a few minutes until D[deoxy(Hb+Mb)] increase reached a plateau.  
Results were expressed as mean values ± standard deviation (
_
x  ± SD). The statistical significance 
of differences between means was checked by paired Students’ t-test. The level of significance was 
set at P<0.05. 
 
RESULTS  
No side effects of therapy were observed. We did not use validated scales to assess quality of life, 
however, the patients reported a progressive subjective improvement of daily performance, and 
particularly less fatigability both at work and during activities of daily living. After 9 months of 
treatment one of the patients spontaneously started to perform 2-3 times per week short sessions 
(about 15 minutes) of exercise on a stationary bicycle. 
One patient did not perform the spirometry tests. Data obtained in the other 3 patients are shown in 
Figure 1. In BEFORE FVC and FEV1 were, on the average, 73 and 74% of the predicted normal 
value, respectively. For both variables, either expressed in L or as a percentage of the predicted 
value, ERT was associated with a slight improvement, which, however, did not reach statistical 
significance, presumably as a consequence of the low number of patients (see also below).  
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The patients tolerated the exercise testing relatively well and none of them complained of 
significant discomfort, pain or delayed onset muscle soreness. Peak values of work rate, O2, CO 
and (∆[deoxy(Hb+Mb)] are shown in Figure 2 (also for ∆[deoxy(Hb+Mb)] peak the data were not 
available for one of the patients). O2peak increased by ~10% from BEFORE (1.01 ± 0.42 L/min, 
or 17.2 ± 4.4 ml/kg/min) to AFTER (1.14 ± 0.36 L/min, or 19.7 ± 3.5 ml/kg/min). On the average 
O2peak values obtained in AFTER correspond to ~5 METs, or 5 times the resting energy 
expenditure (1 MET = 3.5 mlO2 · kg-1· min-1), and to ~ 59% of the sex- and age-predicted peak 
value. The increase in O2peak was associated with a clear tendency for an increase in COpeak, 
from 12.3 ± 5.3 L/min to 14.8 ± 4.5 L/min. Both HRpeak (which increased from 134 ± 16 beats/min 
to 145 ± 25 beats/min) and peak stroke volume (from 91 ± 29 mL to 101 ± 21 mL) contributed to 
the increased COpeak. For COpeak, HRpeak and SVpeak the increase, in AFTER vs. BEFORE, did 
not reach statistical significance. The same can be said for ∆[deoxy(Hb+Mb)] peak, taken as an 
estimate of skeletal muscle fractional O2 extraction (for details see [12]).  
 
DISCUSSION 
The major finding of the present study is that in patients with glycogen storage disease type II 
enzyme replacement therapy is associated, over a 12-month period, with a stabilization of 
pulmonary function and with a mild improvement of exercise tolerance.  
Two widely accessible and simple parameters, FVC and FEV1, were used to monitor respiratory 
function. A nonsignificant trend in FVC and FEV1 improvement was observed in all patients. These 
findings are consistent with those recently reported in larger ERT trials on late-onset GSDII patients 
treated for 12 [8], 18 [9] and 36 months [7]. The stabilization or the slight improvement of 
pulmonary function observed in our study, as well as in the previously mentioned ones, is in 
contrast to the progressive deterioration that characterizes the natural course of the disease (annual 
decline of ~ 2-3% in the percentage of predicted FVC [9]).      
ERT increased peak exercise capacity and exercise tolerance. Significantly higher values of 
O2peak AFTER were associated with (and presumably were responsible for) a significant 
improvement of exercise tolerance, as shown by the significantly higher peak work rate values. The 
increase in O2peak was associated with an improvement of COpeak and ∆[deoxy(Hb+Mb)] peak.  
In two of the patients ∆[deoxy(Hb+Mb)] peak values were markedly lower than the values observed 
by our group in healthy subjects, but higher than those obtained on patients with mitochondrial 
myopathies or myophosphorylase deficiency [12]. Interestingly enough, in one patient 
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∆[deoxy(Hb+Mb)] peak values were substantially unchanged compared with those determined at 
rest; in this patient, characterized by the lowest work rate and O2 peak values, the variable was 
unaffected by ERT.  
As nicely discussed by Poole et al. [14], it would be an oversimplification to interpret skeletal 
muscle fractional O2 extraction simply as a result of “muscle factors”. The enhanced peak fractional 
O2 extraction described with training in two of our patients may indeed be the result of a 
combination of factors such as increased bulk blood flow and O2 delivery; enhanced vasodilation 
and capillary recruitment; improved intramuscular matching of O2 delivery and O2 utilization; 
enhanced peripheral O2 diffusion; improved endothelial function; reduced levels of inflammatory, 
catabolic and pro-apoptotic mediators and oxidative stress; increased mitochondrial volume density 
and activity of oxidative enzymes; enhanced oxidative phosphorylation, etc. All these factors, 
which could be at least in part related to a decreased disease-induced damage in muscle tissue, 
could explain (and be a result of) the increased exercise tolerance. 
In late-onset GSDII patients skeletal muscle pathology is extremely heterogeneous, ranging from 
substantially unaffected fibers to a complete destruction of contractile machinery. The pathogenic 
mechanisms of muscle damage are still under debate, but autophagy is increasingly identified as a 
pivotal contributor to muscle destruction and mitochondrial abnormalities have been repeatedly 
found [15]. Regarding the response to ERT, clinical trials have indicated that ERT is effective in 
glycogen clearance in cardiac muscle, whereas a reversal of the damage in skeletal muscle has not 
always been achieved, and highly variable responses between patients should be expected [8,9]. 
Unfortunately, muscle biopsies were not performed in the present study, thus we have no data of the 
degree of muscle damage in the patients in BEFORE and in AFTER. 
As discussed above, the subjective improvement observed by one of the patients during the first few 
months of ERT induced her to spontaneously adopt a home-based light exercise training protocol. 
Thus, it cannot be excluded that the beneficial effects described in the present study after ERT can 
be attributed, at least in part, to the increased level of physical activity. Recently, evidence has been 
provided that ERT and exercise training could have additive positive effects on these patients’ 
exercise tolerance and, ultimately, on their quality of life [2].  
For some of the variables determined in the present study (spirometry data, COpeak, 
∆[deoxy(Hb+Mb)] peak) the observed increases did not reach statistical significance. This could be 
attributed to the low number of patients, which does not allow us to exclude the possibility of a type 
2 error. Thus, the findings need to be validated on a larger group of patients and with a longer 
follow-up period. 
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In conclusion, our findings showed that in late-onset GSDII patients ERT is associated with a mild 
improvement of pulmonary function and exercise tolerance over a 12 month period. The improved 
exercise tolerance seems associated with improvements both in cardiovascular and in skeletal 
muscle functions. The findings need to be validated on a larger group of patients and with a longer 
follow-up period. In addition, the results highlight the role that cardiopulmonary exercise testing, 
with simultaneous non-invasive measurements of pulmonary O2 uptake, cardiac output and skeletal 
muscle oxygenation, can play in the assessment and follow-up of late onset GSDII patients. 
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FIGURE 1. Individual values, expressed either in L or as a percentage of the predicted value, of 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) measured before 
treatment (BEFORE) and after 12 months of ERT (AFTER).  
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FIGURE 2. Individual peak values of work rate (W), oxygen uptake ( O2), cardiac output (CO) 
and ∆[deoxy(Hb+Mb)], expressed as a percentage of the maximal values during a transient limb 
ischemia,  measured before treatment (BEFORE) and after 12 months of ERT (AFTER). 
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ABSTRACT 
Patients with McArdle’s disease (McA) typically show the “second wind” phenomenon, a sudden 
decrease in heart rate (HR) and an improved exercise tolerance occurring after a few minutes of 
exercise. In the present study we investigated whether in McA a first bout of exercise determines a 
second wind during a second bout, separated by the first by a few minutes of recovery.  
Eight McA (44±4 years) and a control group of 6 mitochondrial myopathy patients (MM) (51±6 
years) performed two repetitions (CWR1 and CWR2) of 6-min constant work rate exercise (~50% 
of peak work rate) separated by 6-min (SHORT) or 18-min (LONG) recovery. Pulmonary O2 
uptake ( O2), HR, cardiac output (Q
.
), rates of perceived exertion (RPE), vastus lateralis 
oxygenation (Δ[deoxy(Hb+Mb)], by near-infrared spectroscopy) were determined.  
In McA O2 (0.86±0.2 vs. 0.95±0.1 L.min-1), HR (113±10 vs. 150±13 b.min-1), Q
.
 (11.6±0.6 vs. 
15.0±0.8 L.min-1), RPE (11±2 vs. 14±3) were lower, whereas Δ[deoxy(Hb+Mb)] was higher 
(14.7±2.3 % vs. -0.1±4.6 %) in CWR2-SHORT vs. CWR1; the “overshoot” of Δ[deoxy(Hb+Mb)] 
and the “slow component” of O2 kinetics disappeared in CWR2-SHORT. No differences (vs. 
CWR1) were observed in McA during CWR2-LONG, or in MM during both CWR2-SHORT and -
LONG. 
A second wind phenomenon was observed in McA during the second of two consecutive 6-min 
constant-work rate submaximal exercises. The second wind was associated with changes of 
physiological variables suggesting an enhanced skeletal muscle oxidative metabolism. The second 
wind was not described after a longer (18-min) recovery period. 
KEY WORDS: myophoshorylase deficiency; exercise tolerance; O2 kinetics slow component; 
near-infrared spectroscopy. 
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INTRODUCTION 
Patients with McArdle’s disease (McA) are affected by an autosomal recessive muscle glycogenosis 
(type V) caused by mutations in the gene that encodes muscle glycogen phosphorylase. Absence of 
activity of this enzyme blocks the breakdown of intramuscular glycogen and significantly impairs 
both substrate level phosphorylation from glycolysis and oxidative phosphorylation (44-46). The 
impairment of oxidative metabolism results in a reduced capacity to increase muscle O2 extraction, 
or arterio-venous O2 concentration difference ([C(a-v)O2]), during exercise (14), and leads to a 
significantly lower than normal maximal (or peak) O2 uptake ( O2) (13). McA also present an 
exaggerated cardiovascular response to submaximal exercise, that is, higher heart rate (HR), cardiac 
output (Q
.
), and muscle blood flow values, compared to healthy subjects, for the same submaximal 
O2 (19, 28,29,40,44-46,49), together with a markedly slower adjustment of O2 during constant 
work rate submaximal exercise (17). 
A typical feature of McA is the “second wind” phenomenon (20,31). As first described by Pearson 
et al. (31), the second wind is characterized by the sudden decrease in HR and improvement of 
exercise tolerance after about 8 min of aerobic, dynamic, exercise (walking or cycling). According 
to Vissing and Haller (49), the second wind is pathognomonic for the disease and it is attributable to 
an enhanced sympatho-adrenal response and to an improved delivery of extramuscular energy 
substrates, free fatty acids and glucose, to working muscles, which partially compensates for the 
impaired glycogen breakdown (20). Other studies have demonstrated that the second wind can be 
induced by oral glucose (20). 
No study has so far investigated if in McA a previous bout of exercise can induce a second wind 
phenomenon during a subsequent bout. This would be of interest also from a clinical point of view, 
considering that many activities of everyday life entail bouts of exercise separated by recovery 
periods. It could also allow patients to develop strategies (for example, having an exercise bout 
preceded by a “warm up” activity) which could increase their exercise tolerance. Moreover, in no 
previous studies the second wind phenomenon has been characterized in terms of variables 
intrinsically related to an enhanced skeletal muscle oxidative metabolism and to an increased 
exercise tolerance, such as a reduced amplitude of the “slow component” of the O2 kinetics (23) 
and a reduced O2 cost of exercise.  
 
Also in healthy subjects a vigorous “priming” or warm-up exercise can determine a reduced 
amplitude of the slow component and an increased exercise tolerance during a subsequent high-
intensity exercise bout (4). The mechanism(s) responsible for this phenomenon may comprise 
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increased muscle O2 availability, greater muscle oxidative enzyme activity and carbon substrates 
supply, and altered motor unit recruitment profiles (7,18,21). Thus, at least in part (see the increased 
carbon substrates supply) the mechanisms potentially responsible for the “priming effect” in healthy 
humans could also be responsible for the second wind phenomenon in McA. It should be noted, 
however, that the priming phenomenon does not determine in healthy humans a lowering of HR (4), 
whereas lower HR (and Q
.
) are prominent effects in the second wind. In any case, in the present 
study the presence of a second wind phenomenon during a second bout of exercise will be 
evaluated also in a control group of patients affected by a mitochondrial myopathy (MM), who have 
similar exercise tolerance of McA (8,14), but in whom a second wind phenomenon has never been 
demonstrated. Thus, if the effects described during the second exercise bout would appear only in 
McA, this would represent strong (although indirect) evidence that they are related to a second wind 
phenomenon; on the other hand, if the effects would appear also in MM they would likely be 
related to a priming effect. 
 
In the present study we hypothesize that in McA, but not in MM, a preceding bout of constant work 
rate submaximal exercise would determine, during a subsequent bout, a second wind phenomenon. 
Apart from the hallmark index of increased exercise tolerance, represented by lower rates of 
perceived exertion, more “traditional” signs of the second wind (lower HR, lower Q
.
, increased O2 
extraction) were sought after, together with other “ancillary” signs of increased exercise tolerance 
(lower E, lower R). In addition, we sought to determine if the second wind was associated with a 
decrease or with a disappearance of the slow component of the O2 kinetics, with a lower O2 cost 
of exercise, with a decrease of transient unbalances between O2 delivery and O2 utilization within 
skeletal muscles (as determined by NIRS [11,36,43]); these findings would point to an enhanced 
performance of skeletal muscle oxidative metabolism as one of the mechanisms of the second wind. 
As a secondary aim, by arbitrarily choosing a “short” (6 minutes) and a “long” (18 minutes) 
recovery period between exercise bouts, we also tried to get insights (also for practical purposes) 
into the length of the recovery period which would allow the second wind phenomenon to manifest 
itself. Whereas 6 minutes represent a “standard” recovery between two 6-min exercise bouts (see 
e.g. 4), 18 minutes were arbitrarily chosen in order to represent a longer recovery, considering that 
prior exercise combined with an extended recovery period [>15 min (47)] might maximize the 
potential for exercise tolerance to be enhanced (4). 
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By applying on patients methods which have been developed in the exercise physiology laboratory, 
the present study will follow a classic translational approach, with the ultimate aim of increasing the 
exercise tolerance and the quality of life of the patients. 
 
METHODS 
Subjects. Eight McA and six MM were studied. Gender distribution, age, and body mass of McA 
were as follows: 3 males and 5 females, age (mean ± SD) 44 ± 4 yr and body mass 75.9 ± 8.9 kg. 
Gender distribution, age, and body mass of MM were as follows: 5 males and 1 female, age 51 ± 6 
yr and body mass 69.1 ± 7.4 kg. Patients were from the Department of Neuromuscular Diseases, 
Neurological Institute ‘‘Carlo Besta’’ (IRCCS), Milano. The diagnosis of McA and MM was based 
on clinical, morphological, biochemical, and molecular evaluations. Clinical details of the patients 
were similar to those reported in our previous article (14). The degree of functional impairment 
varied from mild (no limitations in activities of everyday life but reduced exercise tolerance) to 
severe (very limited exercise tolerance, impairment in activities of daily living). Exclusion criteria 
were the presence of neoplastic and other major neurological/psychiatric, orthopedic, 
rheumathologic, endocrine, pulmonary, or cardiovascular disorders. The subjects were fully 
informed of any risk and discomfort associated with the experiments before giving their written 
consent to participate to the study, which was approved by the ethics committees of the involved 
institutions. All procedures were in accordance with the recommendations found in the Declaration 
of Helsinki (2000) of the World Medical Association. 
 
Measurements. Experiments were conducted in the morning, a few hours (at least 2 hr) after a light 
breakfast (about 600 kcal, 35 % fat, 55 % carbohydrate and 10 % protein). Patients were not 
following any specific diet. All tests were carried out under medical supervision. Subjects were 
monitored by 12-lead ECG.  
An electromagnetically braked cycle ergometer (Corival; Lode BV, Groningen, The Netherlands) 
was used. Pedaling frequency was digitally displayed to the subjects. Subjects were allowed time to 
gain familiarity with the investigators and the experimental arrangement, were carefully instructed 
about the procedures, and were familiarized with the protocol using short practice runs. 
On the first day the subjects performed an incremental test up to voluntary exhaustion to assess 
peak O2 uptake ( O2 peak). After three minutes of unloaded pedaling, exercise was conducted at 
25-50 W for 5 minutes, and thereafter the work rate was increased by 5-15 W (according to the 
subject’s estimated level of physical fitness) every minute. The exhaustion was defined by: (1) 
inability to maintain the pedaling frequency despite encouragement by the operators; (2) maximal 
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levels of self-perceived exertion, using the validated Borg’s scale; and (3) heart rate (HR) values 
>85 % of the age-predicted maximum. Values of cardiovascular, ventilatory, gas exchange, and 
muscle oxygenation variables determined during the last 30 seconds of the exhausting load were 
considered “peak” values.  
During the second and the third days, the patients performed two repetitions of subsequent 6-min 
constant work rate submaximal exercise (CWR1 and CWR2) (at a work rate corresponding to ~50 
% of peak work rate); in the first case CWR1 and CWR2 were separated by a 6-min recovery 
period (SHORT), whereas and in the second case, (after observing at least two hours of rest) CWR1 
and CWR2 were separated by a 18-min recovery period (LONG). Pedaling frequency was kept at 
~60 rpm and transitions from rest to the imposed load were attained in ~3 s. 
Pulmonary ventilation ( E, in BTPS), O2 consumption ( O2), and CO2 output ( CO2), both in 
STPD, were determined breath-by-breath by a metabolic cart (Vmax29c; SensorMedics, Bilthoven, 
The Netherlands). Expiratory flow was determined by a mass flow sensor (hot wire anemometer). 
O2 and CO2 were determined by continuously monitoring PO2 and PCO2 at the mouth 
throughout the respiratory cycle and from established mass balance equations. Gas exchange ratio 
(R) was calculated as CO2/ O2. HR was determined from the ECG signal. Stroke volume (SV) 
was estimated beat-by-beat by impedance cardiography (Physio Flow; Manatec, Paris, France). The 
accuracy of this device has been previously evaluated, in healthy subjects, during incremental 
exercise on a cycle ergometer, and was found to be “acceptable” (38). Cardiac output (Q
.
) was 
calculated as HR . SV. Systemic peak arterial-venous O2 concentration difference ([C(a-v)O2]) was 
calculated as O2peak/Q
.
peak. At rest and at various times (1, 3, and 5 min) during recovery, 20 
µL of capillary blood was obtained from a preheated earlobe for the determination of blood lactate 
concentration ([La]b) by an enzymatic method (Biosen 5030; EKF, Eppendorf Italia, Milano, Italy). 
Oxygenation changes in the vastus lateralis muscle were evaluated by NIRS (5,10). A portable NIR 
single-distance continuous-wave photometer (HEO-100; Omron, Kyoto, Japan), which adopts an 
algorithm based on diffusion theory (42), was utilized. The instrument provides separate 
measurements of changes in deoxygenated Hb and Mb concentrations, as well as of oxygenated Hb 
and Mb concentrations, expressed in arbitrary units. Details on the method can be found in previous 
studies from our group (15,27,36). Concentration changes of oxygenated Hb + Mb 
(∆[oxy(Hb+Mb)]) and deoxygenated Hb + Mb (∆[deoxy(Hb+Mb)]), with respect to an initial value 
arbitrarily set equal to zero, were calculated and expressed in arbitrary units. The sum of the two 
variables (∆[oxy(Hb+Mb) + deoxy(Hb+Mb)]) is related to changes in the total Hb volume in the 
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muscle region of interest (6,12,25). ∆[deoxy(Hb+Mb)] was taken as a “deoxygenation index”, 
because this variable is relatively insensitive to changes in blood volume (6,25). ∆[deoxy(Hb+Mb)] 
was considered an estimate of skeletal muscle fractional O2 extraction, that is of the ratio between 
O2 consumption and O2 delivery (11,15). ∆[deoxy(Hb+Mb)] data were expressed as a percentage of 
the values determined after the exercise (at least 10 min) by obtaining a maximal deoxygenation of 
the muscle, by pressure cuff inflation (at about 300 mmHg) at the root of the thigh (subject in the 
sitting position on the cycloergometer), for a few minutes until the ∆[deoxy(Hb+Mb)] increase 
reached a plateau. 
 
Kinetics analysis. O2 kinetics were evaluated during transitions from rest to CWR. Breath-by-
breath O2 values obtained during the repetitions of the exercises were time aligned and then 
superimposed for each subject. Average O2 values every 10 s were calculated. Data obtained 
during the first 20 s of the transition (‘‘cardiodynamic’’ phase) (37) were excluded from analysis. 
Thus, O2 kinetics analysis focused on the ‘‘phase 2’’ (or ‘‘fundamental’’ component) of the 
response, which more closely reflects gas exchange kinetics occurring in skeletal muscles 
(16,34,50).  
To mathematically evaluate the O2 kinetics, data were first fitted by a monoexponential function 
of the type: 
 
y(t) = yBAS + Af [1  - exp - (x - TDf) / τf ]                                    (Eq. 1) 
 
where yBAS indicates the O2 value at baseline; Af  the amplitude of the O2 response calculated 
between the baseline value and the steady-state value for the fundamental component; TDf is the 
time delay, and τf the time constant of the function for the fundamental component.  
To check the presence of a slow component of the kinetics (21), data were also fit by a double 
exponential function of the type: 
 
y(t) = yBAS + Af [1  - exp - (x - TDf)/ τf ] + As [1  - exp - (x - TDs)/ τs ]                (Eq. 2) 
 
where As, TDs, and τs indicate, respectively, the amplitude, the time delay, and the time constant of 
the slow component of the kinetics. 
€ 
V
.
€ 
V
.
€ 
V
.
€ 
V
.
€ 
V
.
€ 
V
.
€ 
V
.
 67 
Sometimes, after the first exponential rise, O2 increases linearly without reaching a steady-state 
value. In this case, Eq. 2 does not provide a good fit of data. Thus, a third equation was also 
utilized, with an exponential function for the fundamental component and a linear function for the 
slow component (exponential + linear fitting) (38): 
 
y(t) = yBAS + Af [1  - exp - (x - TDf)/Tf ] + S (x-TDs)                                (Eq. 3) 
 
where S (slope) is the angular coefficient of the linear regression of O2 vs. time. 
The equation that best fit the experimental data was determined by the F-test. That is to say, when 
Eq. 2 or Eq. 3 provided a better fit of the data, a slow component (46) of O2 kinetics was present, 
superimposed on the fundamental component. The actual amplitude of the slow component (A’s) 
was estimated as the difference between the average O2 value obtained during the last 20–30 s of 
CWR and the asymptotic value of the fundamental component (15,38). The percentage contribution 
of the slow component to the total amplitude of the response (A’s/Atot) was also calculated (36).  
 
Statistical analysis. Results were expressed as mean values ± standard deviation (x ± SD). The 
statistical significance of differences between two means was checked by Student’s t-test (two 
tailed, unpaired analysis). The effects of the “warm-up” exercise bout (CWR2 vs. CWR1) and of 
the group (McA vs. MM) on the investigated variables were checked by two-way analysis of 
variance (ANOVA). This analysis, however, did not yield a statistically significant difference for 
O2 and E. This is likely attributable to the relatively number of patients in the two groups (McA 
and MM are rare diseases [see also the recent commentary by Ploutz-Snyder J Appl Physiol in 
press]). Thus, analysis of differences between CWR1 and CWR2 in MM and McA was also 
performed by one-way ANOVA. A Tukey’s post hoc test was utilized when significant differences 
emerged upon ANOVA. Data fitting by linear regression or exponential functions was performed 
by the least squared residuals method. Comparisons between fittings with different exponential 
models were performed by F test. The level of significance was set at P<0.05. Statistical analyses 
were performed by a software package (Prism 5.0; GraphPad, San Diego, CA). 
 
RESULTS 
Incremental exercise. Peak values are shown in Table 1. Values were very similar to those 
obtained in McA and MM in a previous study by our group (14) and by others (19,21). O2 peak 
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was ~50 % of that usually obtained in healthy age-matched subjects (30), indicating a severely 
reduced maximal aerobic power. HR values, significantly higher in McA than in MM, corresponded 
to ~96 % of the age–predicted maximum. Q
.
 peak values were only slightly lower than those 
usually obtained in healthy controls (39). As expected for both patients groups, [C(a-v)O2] and peak 
skeletal muscle fractional O2 extraction values were very low. As expected, in McA R peak values 
were relatively low, and [La]b peak values were not higher than those determined at rest (1.2 ± 0.1 
mM). For the other variables no differences were observed between McA and MM.  
 
Constant work rate exercises. Figure 1 shows typical examples of HR time-courses of a MM 
(upper panels) and of a McA (lower panels) during SHORT (left panels) and LONG (right panels). 
In McA, during SHORT (but not during LONG) HR values at the end of CWR2 were markedly 
lower (by about 50 beats . min-1) than during CWR1. This second wind phenomenon is indicated by 
the arrow. No differences between CWR1 and CWR2 were observed in MM, either during SHORT 
and LONG.  
Mean (± SD) values determined in the last ~30 s of CWR1 and CWR2 (SHORT and LONG 
recovery) are presented in Table 2. In McA during SHORT O2, CO2, E, R, HR, Q
.
 and RPE 
values were significantly lower in CWR2 vs. CWR1. On the other hand, [La]b, [C(a-v)O2] and 
∆[deoxy(Hb+Mb)] were significantly higher in CWR2 vs. CWR1. No significant differences were 
observed between CWR1 and CWR2 in LONG. As for MM, no significant differences were 
observed between CWR1 and CWR2, both in SHORT and in LONG.  
 
O2 and ∆[deoxy(Hb+Mb)] kinetics. Typical individual examples of O2 kinetics of a MM 
(upper panels) and of a McA (lower panels) during SHORT (left panels) and LONG (right panels) 
are shown in Figure 2. As for McA, O2 values did not reach a steady-state and a slow component 
was evident in CWR1. During CWR2 the slow component disappeared in SHORT, but not in 
LONG. This second wind phenomenon is indicated by the arrow. A slow component was not 
observed in MM, both during CWR1 and CWR2 (SHORT and LONG).  
The parameters of O2 kinetics are shown in Table 3. In both groups TDf, τf and Af values were 
not significantly different in CWR1 vs. CWR2 (both in SHORT and in LONG). Gain values (G) 
were calculated as Δ O2 ( O2 at the end of CWR minus resting O2) divided by work rate. A 
slow component, corresponding to ~15 % of the total amplitude of the response, was present in all 
McA in CWR1. In six McA the slow component was best described by a linear function (Eq. 3). In 
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CWR2-SHORT, but not in CWR2-LONG, the slow component disappeared. No slow component 
was evident in any MM. In McA A’s, A’s/Atot and G values were significantly lower in CWR2 vs. 
CWR1 in SHORT, but not in LONG. In MM no differences were observed for G values in CWR1 
vs. CWR2 (both in SHORT and in LONG). In both groups of patients G values were substantially 
higher that those usually observed in normal subjects (∼10 ml . min-1 . watt-1), independently from 
the presence of the slow component. 
 
Δ[deoxy(Hb+Mb)] kinetics are shown in Figure 3. In MM, in all conditions there was an initial and 
transient increase (“overshoot”) of Δ[deoxy(Hb+Mb)] (occurring after ~45 s of exercise), which 
was followed by a steady state. Δ[deoxy(Hb+Mb)] values at the peak of the overshoot were 
significantly higher than at steady state, for both CWR1 (24.9 ± 5.1 % vs. 6.2 ± 3.0 %) and CWR2 
(21.9 ± 4.5 % vs. 6.0 ± 5.4 % and 21.5 ± 5.4 % vs. 6.9 ± 3.5 %, respectively in SHORT and 
LONG). In McA values at the peak of the overshoot were higher than those at steady state during 
CWR1 (27.5 ± 6.0 % vs. -0.1 ± 4.6 %) and during CWR2-LONG (24.9 ± 6.7 % vs. 1.9 ± 1.0 %), 
whereas in CWR2-SHORT no decrease of the variable was observed after the initial increase (no 
overshoot was described). 
 
DISCUSSION 
We observed in McA, during the second (CWR2) of two 6-min constant work rate exercises, 
carried out at ~50 % of peak work rate, and separated by 6 minutes of recovery (SHORT), 
significant changes indicating an improved exercise tolerance and an enhanced oxidative 
metabolism, such as lower (vs. the first exercise bout [CWR1]) RPE, HR, Q
.
, R, E, the 
disappearance of the slow component of O2 kinetics and a reduced O2 cost of exercise, a slightly 
increased skeletal muscle fractional O2 extraction and the disappearance of signs of transient 
unbalance between O2 delivery and O2 utilization within skeletal muscles (overshoot). No 
differences between CWR1 and CWR2 were described when the recovery period was extended to 
18 minutes (LONG). 
 
Can the differences mentioned above be considered an expression of a “second wind phenomenon” 
(1,2,20,46,49), or could they be simply related to a “warm up” or “priming” effect of the first 
exercise bout, as described also in healthy subjects (see e.g. 4), substantially in terms of a reduced 
amplitude of the slow component? The answer to this question is not straightforward, but several 
pieces of evidence appear in favor of a second wind phenomenon. The profound changes described 
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in the present study in McA during CWR2-SHORT, such as the disappearance of the slow 
component of O2 kinetics, the substantially lower E, HR, Q
.
, RPE, etc., and the slightly higher 
fractional O2 extraction, appear qualitatively and quantitatively quite different from those usually 
observed in healthy subjects following a priming exercise. Just to make an example, in McA HR 
values were on average 37 beats . min-1 lower during CWR2-SHORT vs. CWR1, whereas the 
priming effect does not usually affect HR values in healthy subjects (see e.g. 4). Moreover, in the 
“control” population represented by MM, which has a similar exercise tolerance compared to McA 
(see also 14,45) but do not manifest any second wind phenomenon, no differences were observed in 
CWR2-SHORT vs. CWR1. In any case, independently from the definition which is given to the 
phenomenon, our data demonstrate that in McA a first bout of exercise affects several 
cardiovascular, ventilatory and metabolic variables, enhances skeletal muscle oxidative metabolism 
and substantially improves exercise tolerance during a subsequent bout carried out a few minutes 
after the first. The finding has an obvious clinical interest.  
 
The second wind is usually attributed to an improved delivery of extramuscular energy sources, 
particularly glucose, to working muscles, following an enhanced sympathoadrenal response (20). 
The phenomenon has been previously demonstrated in McA patients during prolonged exercise 
(20,49) or after sucrose administration (1,2,20), and is considered pathognomonic for the disease 
(49). The second wind has been described in literature as a lower HR (20), lower RPE (48), 
increased [C(a-v)O2] (20) and increased [La]b (20) during submaximal exercise, or increased peak 
work rate and peak O2 (20).  
Our results demonstrate that the second wind is also characterized by changes of other 
physiological variables clearly related to exercise tolerance, such as the slow component of O2 
kinetics and the related O2 cost of exercise (23). As shown in Figure 2 (see CWR1 in McA), the 
slow component determined a progressive increase in O2 during constant work rate exercise, 
suggesting a progressive increase in the O2 cost of exercise, which is directly related with fatigue 
(23). Our group has recently demonstrated (41) that in obese patients the slope of the slow 
component is inversely related to the time of exhaustion. In the present study the slow component 
was eliminated in CWR2-SHORT. 
In our study the enhanced exercise tolerance observed in McA during CWR2-SHORT vs. CWR1 
was associated with a slightly but significantly increased skeletal muscle fractional O2 extraction (as 
determined by NIRS), confirming the data obtained by different methods by Haller & Vissing (20). 
The data demonstrate that the second wind partially corrects the impairment of oxidative 
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metabolism which is one of the pathophysiological hallmarks of the disease (14,17,20,45,46). 
Skeletal muscle fractional O2 extraction in McA, however, remained quite lower than that usually 
described in healthy subjects (36), as well as in other populations in which skeletal muscle 
oxidative metabolism is known to be impaired, such as ageing subjects (13), subjects exposed to 
bed-rest deconditioning (36) or in patients such as heart transplant recipients (27). 
In McA the “overshoot” of the ∆[deoxy(Hb+Mb)] kinetics, which was evident during CWR1, 
disappeared in CWR2-SHORT (but not in CWR2-LONG). According to Ferreira et al. (11), the 
overshoot is a sign of a relatively inadequate muscle O2 delivery vs. muscle O2, and could lead to 
a reduced microvascular O2 pressures and to a lower blood-to-myocyte “driving force” for 
peripheral O2 diffusion. The overshoot phenomenon, which suggests an impaired intramuscular 
matching between O2 delivery and O2 utilization, was observed in the present study also in MM, 
and in previous studies in subjects undergoing bed rest deconditioning (36) and in patients with 
chronic heart failure (43). In the present study the overshoot disappeared during CWR2-SHORT in 
McA, but not in MM; this suggests that an improved intramuscular matching between O2 delivery 
and O2 utilization is likely associated with the second wind phenomenon. The possible mechanisms 
underlying the impaired intramuscular matching between the mentioned variables are discussed in 
detail in Poole et al. (35), and seem to be related to nitric oxide bioavailability. Also this component 
of the second wind phenomenon was no longer present after 18 minutes of recovery (CWR2-
LONG). 
 
In the present study the work rate of CWR1 and CWR2 cannot be clearly characterized as 
“moderate” or “heavy” or “severe” (50). As was the case with previous authors (9), in our McA 
patients we could not determine the gas exchange threshold (GET). It should be remembered that 
these patients are characterized by the absence of any blood lactate increase during exercise, even at 
exhaustion, as a consequence of the “blocked” glycogenolysis. GET is usually utilized to 
discriminate between “moderate” exercise (below GET, with no slow component of O2 kinetics) 
and “heavy” exercise (above GET, with a slow component which eventually reaches a steady state). 
In normal subjects, exercises in which the slow component does not reach a steady-state and O2 
keeps increasing as a function of time during the constant work-rate exercise (as in McA during 
CWR1, see Fig. 2), until O2 peak is reached and fatigue ensues, are considered to be in the 
“severe” exercise domain, above the “critical power” (23). Thus, for McA of the present study the 
exercise could be defined as “severe” in CWR1 and “moderate” in CWR2-SHORT (24,52).  
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In conclusion, in the present study carried out on McA patients we demonstrated, for the first time, 
a “second wind” phenomenon during the second of two consecutive submaximal 6-min constant 
work rate exercises, separated by 6 minutes of recovery. The second exercise was indeed 
characterized by significantly lower (compared to the first exercise bout) rate of perceived exertion, 
heart rate, cardiac output, pulmonary ventilation, gas exchange ratio, and by slightly higher skeletal 
muscle fractional O2 extraction. For the first time we also demonstrated that the second wind was 
associated with signs of enhanced skeletal muscle oxidative metabolism such as the disappearance 
of slow component of pulmonary O2 kinetics (and therefore with a lower O2 and a lower O2 
cost of exercise), and the disappearance of signs of transient mismatch between O2 delivery and O2 
utilization in skeletal muscle. We did not observe the second wind phenomenon when the recovery 
period between the two exercise bouts was longer (18 minutes).  
Considering that many activities of everyday life are characterized by bouts of exercise separated 
by recovery periods, the present results appear of interest also from a clinical and practical point of 
view. They also give a scientific background to strategies which are often already empowered by 
McA patients in order to increase their exercise tolerance: for example, having an exercise bout 
preceded by a few minutes by a “warm up” activity. By following a classic translational approach, 
the present study applied on patients methods which have been developed in the exercise 
physiology laboratory, with the ultimate aim of increasing their exercise tolerance and quality of 
life. 
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FIGURE 1. Typical individual examples of heart rate (HR) kinetics during the first (CWR1) and 
the second (CWR2) constant work rate exercise in MM (upper panels) and McA (lower panels). 
Data obtained with 6 (SHORT) or 18 minutes (LONG) of recovery are presented in the left and 
right panels, respectively. The vertical hatched lines indicate the transitions from rest to the 
imposed work rate, and from the imposed work rate to recovery. The second wind phenomenon is 
indicated by the arrow. See text for further details. 
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FIGURE 2. Typical individual examples of pulmonary O2 uptake ( O2) kinetics during the first 
(CWR1) and the second (CWR2) constant work rate exercise in MM (upper panels) and McA 
(lower panels). Data obtained with 6 (SHORT) or 18 minutes (LONG) of recovery are presented in 
the left and right panels, respectively. The vertical hatched lines indicate the transitions from rest to 
the imposed work rate, and from the imposed work rate to recovery. The functions fitting the 
fundamental component (continuous line) and the slow component (hatched lines) are shown. 
A’s/Atot data are also presented. The second wind phenomenon is indicated by the arrow. See text 
for further details. 
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FIGURE 3. Mean (± SD) values every second of skeletal muscle fractional O2 extraction 
(Δ[deoxy(Hb+Mb)]) during the first (CWR1) and the second (CWR2) constant work rate exercise 
in MM (upper panels) and McA (lower panels). Data obtained with 6 (SHORT) or 18 minutes 
(LONG) of recovery are presented in the left and right panels, respectively. Δ[deoxy(Hb+Mb)] data 
are expressed as a percentage of Δ[deoxy(Hb+Mb)] changes during ischemia. The vertical hatched 
lines indicate the transitions from rest to the imposed work rate, and from the imposed work rate to 
recovery. The second wind phenomenon is indicated by the arrow. See text for further details. 
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Mean (± SD) Values. O2, oxygen uptake; CO2, CO2 output; R, gas exchange ratio; E, 
pulmonary ventilation; Vt, tidal volume; fR, breathing frequency; PetO2, end-tidal O2 partial 
pressure; PetCO2, end-tidal CO2 partial pressure; [La]b, blood lactate concentration; RPE, rate of 
perceived exertion; HR, heart rate; SV, stroke volume; Q
.
, cardiac output; [C(a-v)O2], systemic 
arterial-venous O2 concentration difference; Δ[deoxy(Hb+Mb)], muscle oxygenation index obtained 
by NIRS. #P < 0.05, significantly different from the corresponding value obtained in MM. See text 
for further details.  
 
 
 
Mean (± SD) values of O2, oxygen uptake; CO2, CO2 output; R, gas exchange ratio; E, 
pulmonary ventilation; Gain, Δ O2 ( O2 at the end of CLE minus resting O2) divided by work 
rate; [La]b, blood lactate concentration; RPE, rate of perceived exertion; HR, heart rate; SV, stroke 
volume; Q
.
, cardiac output; [C(a-v)O2], systemic arterial-venous O2 concentration difference; 
Δ[deoxy(Hb+Mb)], muscle oxygenation index obtained by NIRS. *P < 0.05, significantly different 
from the corresponding value obtained in CWR1. See text for further details. 
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 Mean (± SD) values of baseline (yBAS); time delay (TDf), time constant (τf), amplitude (Af) of 
the fundamental component; actual amplitude (A’s) of the slow component; and total amplitude of 
the response (Atot). *P < 0.05, significantly different from the corresponding value obtained in 
CWR1. NA = not applicable. See text for further details.  
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ABSTRACT 
 
Evidence has been provided that aerobic training should be considered as a treatment for 
Mitochondrial myopathies (MM) and myophosphorylase deficiency (McArdle’s disease, McA). 
Aim of the present study was to utilize non−invasive methods of functional evaluation, specifically 
aimed at oxidative metabolism at the skeletal muscle level, in order to evaluate the effects of an 
aerobic exercise training. 6 MM and 7 McA patients underwent 12 weeks of exercise training 
(4v/weeks) at home at an heart rate (HR) corresponding to about 65-70% of the maximal HR. 
Oxygen uptake (V’O2) and skeletal muscle (vastus lateralis) fractional O2 extraction (by NIRS) 
were assessed during incremental and moderate and high-intensity constant-load exercises before 
(BEFORE) and at the end (AFTER) of the training period. V’O2peak increased significantly with 
training both in MM (from 14.7 ± 3.0 [x ± SD] mL/kg/min BEFORE to 17.6 ± 3.3 AFTER) and in 
McA (from 18.5 ± 4.7 mL/kg/min to 21.6 ± 5.1 mL/kg/min). Peak skeletal muscle (vastus lateralis) 
fractional O2 extraction increased with training both in MM (from 22.0 ± 6.7 % to 32.6 ± 5.9) and 
in McA (from 18.5 ± 6.2 % to 37.2 ± 7.2). The time constants of VO2 kinetics in moderate-intensity 
constant-load exercise were significantly reduced in MM (45.1 ± 6.6 s BEFORE vs. 35.9 ± 4.2 s 
AFTER) and in McA who had presented, before training, markedly slow kinetics of adjustment of 
VO2. During the high-intensity constant-load exercise, MM patients showed, after training, clear 
signs of increased exercise tolerance, such as lower HR (from 134.3 ± 10.8 b/min to 120.8 ± 9.2) 
and lower scores at the Borg’s scale of perceived exertion (from 14.5 ± 1.2 to 12.3 ± 1.5). In MM 
and McA patients a 12 weeks aerobic training program significantly increased exercise tolerance. 
Our findings confirm that near infrared spectroscopy and VO2 kinetics can effectively detect the 
functional improvements obtained by training, yielding insights also on the mechanisms of the 
improvements at the pathophysiological level.  
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INTRODUCTION 
 
Metabolic myopathies are an heterogeneous group of disorders characterized by derangements of 
glycogen or lipid metabolism or mitochondrial function due to genetic mutations leading to defects 
of the main pathways of energy provision in skeletal muscle fibers. In some of these myopathies, 
such as myophosphorylase deficiency (McArdle’s disease, McA) (Lewis&Haller 1986, Haller 
&Vissing 2000) or mitochondrial myopathies (MM) (Haller&Vissing 2000, Tarnopolski &Raha 
2005, Zeviani &Di Donato 2004) the genetic defect significantly impairs oxidative metabolism. In 
MM the mutation(s) in the mitochondrial genome (sporadic or maternally inherited) or in the 
nuclear genome (autosomally inherited) causes the impairment of the mitochondrial respiratory 
chain and, consequently, a reduced capacity to increase O2 extraction. In McA the absence or low 
activity of the myophosphorylase enzyme causes an incapacity to break down intramuscular 
glycogen, making impossible for the muscle to mobilize glycogen deposits during the exercise. The 
reduced or absent flux of substrates along the glycolytic pathway impairs one of the two main 
routes of supply of substrates to the tri−carboxylic acids cycle, and disrupts the delicate interplay 
between carbohydrate and lipid metabolism. This leads to a significant impairment of oxidative 
metabolism, to a reduced capacity to increase O2 extraction during exercise and to a lower than 
normal maximal aerobic power (V’O2 peak) (REF).  
In many MM and McA the impairment of oxidative metabolism lead to a phenotype characterized 
by a reduced exercise tolerance and easy fatigability, often associated with progressive weakness 
and myalgia, significantly affecting the patients’ quality of life. Nevertheless these patients may not 
present objective findings on neurological examination such as muscle atrophy or force impairment, 
and electromyography and routinely laboratory evaluation are frequently normal. Thus,  the 
diagnosis of metabolic myopathy may be difficult and often delayed (Sharp & Haller, 2014) until an 
invasive procedure like needle biopsy, considered the gold standard diagnostic test, is performed.  
A possibility to quantify and serially monitor such impairment by non−invasive tools would be of 
great interest for clinicians, who need an objective, quantitative and longitudinal evaluation of the 
impairment to be used in the follow−up of patients, as well as in the assessment of therapies or 
other interventions. Our group have recently applied to MM and McA two methods of functional 
evaluation which had been previously utilized in our laboratory on healthy subjects (Grassi et al. 
2003), elderly subjects (Ferri et al. 2007), following training (Porcelli et al 2014), on subjects with 
microgravity−induced muscle atrophy (Lanfranconi et al. 2008) as well as on other types of patients 
(Borrelli et al. 2003, Lanfranconi et al. 2006) to evaluate oxidative metabolism at the skeletal 
muscle level. The variables of functional evaluation which we evaluated were (Grassi et al. 2007, 
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Grassi et al. 2014): A). Skeletal muscle oxygenation indices during exercise, obtained by 
near−infrared spectroscopy (NIRS) and taken as estimates of the capacity of O2 extraction. B) 
Kinetics of adjustment of pulmonary O2 uptake (V’O2 kinetics) during the transition from rest to 
exercise. 
NIRS is a non−invasive method that allows to monitor muscle oxygenation on the principle that the 
near−infrared (NIR) light absorption characteristics of haemoglobin (Hb) and myoglobin (Mb) 
depend on their O2 saturation. Theoretical basis, practical applications, advantages and limitations 
of NIRS have been extensively reviewed (Ferrari et al. 2004). Briefly, absorption changes of NIR 
light in muscle reflect changes in oxygenation at the level of small blood vessels (small arterioles 
and venules), capillaries, and intracellular sites of O2 transport and uptake. The obtained 
oxygenation indices are the result of the balance between O2 delivery and O2 uptake (V’O2) in the 
portion of tissue under consideration, being therefore conceptually similar to fractional O2 
extraction. In a study (Grassi et al. 2007) conducted on MM and McA we determined by NIRS 
concentration changes of deoxygenated Hb + Mb (Delta[deoxy(Hb+Mb)]), and the values obtained 
at exhaustion (Delta[deoxy(Hb+Mb)]peak) during an incremental exercise were taken as an index 
of the maximal capacity of O2 extraction. Delta[deoxy(Hb+Mb)]peak was significantly lower in 
MM and McA compared to controls and Delta[deoxy(Hb+Mb)]peak was also significantly 
correlated with V’O2 peak. Since the reduced maximal capacity of O2 extraction represents the key 
patho−physiological mechanism responsible for the reduced V’O2 peak and exercise tolerance, it is 
conceivable that in MM and McA Delta[deoxy(Hb+Mb)]peak determined by NIRS can identify and 
quantify the impairment of oxidative metabolism. A limitation of that approach was represented by 
the need for the patient to perform an incremental exercise to exhaustion, which may not be feasible 
in the most compromised patients. Thus, some variables of functional evaluation to be determined 
during submaximal exercise tests were needed. We hypothesized that a possibility could derive 
from the determination of the kinetics of adjustment of pulmonary V’O2 during transitions from rest 
to submaximal exercise (Whipp et al. 2002). It is generally accepted that pulmonary V’O2 kinetics 
allow a specific evaluation of skeletal muscle oxidative metabolism (Grassi, 2007). This concept 
should apply even more strictly to patients with metabolic myopathies, in whom the impairment of 
oxidative metabolism is by definition located in skeletal muscles. In a study conducted by our group 
on MM and McA (Grassi et al. 2014) V’O2 kinetics were indeed significantly slower (as indicated 
by the higher time constants) in MM and McA compared to the control groups. Time constants of 
V’O2 kinetics were significantly and negatively correlated with the NIRS−derived oxygenation 
index which, as discussed above (Grassi et al. 2007) allows to estimate the maximal capacity of O2 
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extraction by skeletal muscle. Thus, slower pulmonary V’O2 kinetics were associated with an 
impaired maximal capacity of O2 extraction. 
At present the therapeutic interventions available for patients with metabolic myopathies are very 
limited (REF.). A possibility could derive from exercise training. As mentioned above, in many 
MM and McA the reduced exercise tolerance and the associated easy fatigability are often the main 
symptoms and may significantly affect the patients’ quality of life. Recent studies have 
demonstrated that both in MM (Taivassalo et al. 2001, Taivassalo &Haller 2005, Jeppesen et al. 
2006, Taivassalo et al. 2006) and in McA patients (Haller et al. 2006, Mate−Muñoz et al. 2007, 
Ollivier et al 2005a) moderate−intensity aerobic exercise training is safe and effective in increasing 
exercise tolerance and in improving quality of life. Taivassalo et al. (2006) demonstrated that 14 
weeks of moderate exercise training determined, in MM with single, large−scale mtDNA 
mutations, no changes in the level of mutated mtDNA, but significantly improved exercise 
tolerance and peak work capacity. These improvements were associated with an improved capacity 
for skeletal muscle O2 extraction. Thus, training affected positively the key patho−physiological 
mechanism responsible for the disease. Interestingly, in MM the main effect of aerobic training 
(increased capacity of O2 extraction) was quite different from that (increased capacity of O2 
delivery by the cardiovascular system) usually described in normal subjects. As for McA, aerobic 
training significantly increased work capacity, V’O2peak, peak cardiac output and level of oxidative 
enzymes in skeletal muscle (Haller et al. 2006). Thus, in McA exercise training would improve 
exercise tolerance by increasing both the capacity to deliver blood−borne fuels (on which muscle 
oxidative metabolism critically depends, since glycogen breakdown is blocked) and the capacity by 
the metabolic machinery to utilize these fuel by oxidative metabolism. 
The positive effects of exercise training in patients with metabolic myopathies are further confirmed 
by the observation that when in MM patients training is interrupted (“deconditioning”) the benefits 
obtained by the previous training regimen substantially disappear (Jeppesen et al. 2006). In 
addition, two studies have shown that in McA an increase in physical activity level was associated 
with an amelioration of clinical symptoms and the VO2peak was 23% higher in physical active 
patients compared to the inactive patients, supporting the conclusion that physical activity improves 
exercise capacity (Ollivier et al 2005b, Lucia et al 2012). 
The main aim of the present study was to utilize the above−mentioned non-invasive tools of 
functional evaluation of skeletal muscle oxidative metabolism in order to evaluate the effects of a 
program of home−based moderate−intensity aerobic exercise training on MM and McA patients. 
We hypothesized improved exercise tolerance (as evidenced by increases in V’O2peak and gas 
exchange threshold) and improved quality of life after training. More specifically, these 
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improvements should be associated with improvements in the capacity of O2 extraction by skeletal 
muscle, determined through the analysis of muscle oxygenation indices obtained by NIRS, and a 
faster pulmonary V’O2 kinetics during transitions from rest to moderate−intensity exercise. The 
results will confirm the utility of the proposed non−invasive methods in the follow−up of patients 
as well as in the evaluation of the effects of therapies or rehabilitation interventions. 
 
MATERIALS AND METHODS 
Subjects. 7 patients of both sexes with with myophosphorylase deficiency (McArdle’s disease, 
McA) and 6 patients of both sexes with mitochondrial myopathies (MM) were recruited for the 
study. Gender distribution, age, and body mass for the two groups of patients were as follows: MM, 
4 males (M) and 2 females (F), age (X±SD) = 51±16 yr, body mass = 69.1±18.1 kg; McA, 3 M and 
4 F, age = 41±13 yr, body mass = 71.2±22.9 kg. Patients were from the Department of 
Neuromuscular Diseases, Neurological Institute ‘‘Carlo Besta’’ (IRCCS), Milano. The patients 
were recruited by a Medical Doctor in charge of their clinical assistance. Exclusion criteria were the 
presence of neoplastic and other major neurological/psychiatric, orthopedic, rheumathologic, 
endocrine, pulmonary, or cardiovascular disorders. Patients of age <18 and >60 years and patients 
not capable of performing exercises on a cycloergometer were excluded. The diagnosis of 
metabolic myopathy was based on clinical, morphological, biochemical, and molecular evaluations. 
The initial clinical evaluation was carried out in the occasion of the recruitment of the patients.  The 
protocol included a detailed anamnestic evaluation, general physical and neurologic examinations 
and muscle strength evaluations. Particular enphasis was put on the history related to exercise 
tolerance, habitual physical activity, signs and symptoms related to exercise and physical activity. 
Routine hematological examination (including CPK, LDH, transaminase, aldolase), an ECG and a 
cardiological evaluation was performed. Clinical details for the MM and McA patients were similar 
to those reported in our previous articles (Grassi et al. 2006 e 2009). Their degree of functional 
impairment varied from mild—virtually absent (no limitations in activities of everyday life, no 
significant exercise intolerance)—to severe (very limited exercise tolerance, impairment in 
activities of daily living). Needle muscle biopsy from quadriceps or deltoid was obtained under 
local anesthesia and analyzed by histological and hysto−enzymatic reactions (including Oil−Red−O 
staining for lipid, PAS staining for glycogen, NADH, SDH, Cox staining for mitochondrial 
analysis). Activities of enzymes of respiratory chain, glycolytic enzymes, and CPT were 
determined. Molecular biology end genetic tests were also carried out.  
The subjects were fully informed of any risk and discomfort associated with the experiments before 
giving their written consent to participate to the study, which was approved by the ethics 
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committees of the involved institutions. All procedures were in accordance with the 
recommendations found in the Declaration of Helsinki (2000) of the World Medical Association. 
Study design. This was an open interventional (TRAINING) study in which each patient acted as 
the control for herself/himself. Each patient was involved in the study for 9 months. During the first 
3 month−period (BASELINE) the patients were invited to keep the same level of habitual physical 
activity they had before entering the study. During the second 3 month−period (TRAINING) the 
subjects underwent the training protocol (see below for further details). During the third 3 
month−period (FOLLOW UP) the patients were free to adjust at their will their level of physical 
activity. Habitual physical activity and quality of life (see below) were evaluated before (BEFORE) 
and after (AFTER) the training period, as well as after the post−training follow−up (POST3). The 
functional evaluation of oxidative metabolism (see below) was performed before (BEFORE) and 
after (AFTER) the training period. 
Exercise training. The training period lasted 12 weeks. The first 1−2 training sessions were 
conducted in the hospital, under the supervision of a researcher, who was in charge of giving 
adequate instructions to the patients about the training procedures. The patients conducted the 
remaining training sessions at home. Training sessions was 4 per week. Each session lasted about 1 
hour, and began with about 10−15 minutes of stretching exercises and exercises aimed at 
optimizing flexibility and balance. These activities were followed by 30 minutes (for the first 6 
weeks) or by 45 minutes (for the remaining 6 weeks) of moderate−intensity aerobic training, 
conducted on a stationary cycloergometer. Patients were allowed to split at their will the 30− or 45− 
min total daily duration of the training session into combinations of 15−min or 30−min training 
periods, carried out during the same day. The possibility to split the training session into parts was 
aimed at enhancing the compliance to the training regimen. Exercise intensity was chosen as to 
correspond to about 70% of maximal HR, determined for each subject during the incremental 
exercise described above. HR was displayed and recorded during each exercise session utilizing a 
Polar NV chest band and watch (Polar Electro, Finland). The cycloergometer recorded on a card the 
power output vs. time profile of each training session (Figure 1). Every week the patients (or 
someone closed to them) sent these data by e−mail in order to check the compliance and adherence 
of the patients to the training regimen. The patients were instructed to maintain, during the training 
period, the same level of physical activity (apart from the training sessions) which characterized the 
3 months preceding training (BASELINE). The patients were also instructed to keep a diary for 
each day of training. All forms of physical activity (type, duration, intensity) outside the training 
protocol were recorded on the diary. The diary was kept also during the 3 months of pre−training 
baseline, as well as during the 3 months of follow−up after the completion of the training protocol.  
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Physical activity Assessment. The physical activity of patients was assessed using the Sensewear 
Armband (SWA) (BodyMedia Inc., Pittsburgh, USA), a tri-axial accelerometer-based activity 
monitor coupled with several heat-related sensors (heat flux, body temperature and galvanic skin 
response). The SWA has been shown to provide valid estimates of energy expenditure during 
exercise (Johannsen DL, Calabro MA, Stewart J, Franke W, Rood JC, Welk GJ. Accuracy of 
armband monitors for measuring daily energy expenditure in healthy adults. Med Sci Sports Exerc. 
2010; 42 (11): 2134–40) and free-living physical activities (Berntsen S, Hageberg R, Aandstad A, et 
al. Validity of physical activity monitors in adults participating in free-living activities. Br J Sports 
Med. 2010; 44 (9): 657–64) in previous studies. The SWA was placed on the patient's right arm 
over the triceps muscle and worn for three consecutive days. The patients were instructed to 
continue their normal life while wearing SWA for 24h a day, except while doing water-related 
activities (i.e showering). Data from SWA were processed using a proprietary software package (v 
8.0) and were expressed in kcal·min-1. 
Quality of life assessment. The quality of life and physical functioning was determined by a 
validated survey, the Short Form Health Survey Questionnaire (SF−36) (Ware &Sherbourne 1992). 
SF-36 assesses eight health domains using 35 questions: the questions for the physical function are 
10, physical role limitation 4, body pain 2, general health 6, vital force 4, social function 2, 
psychological role limitation 3 and mental health 5 (Ware &Sherbourne 1992). The range of score 
was of 0-100. For each of the eight health domains, a scale score was calculated with the higher 
scores representing better health status. A complete description of the scoring and measurement 
model is described elsewhere (Garratt et al 1993). 
Functional evaluation of oxidative metabolism.  The tests were conducted in a laboratory set up 
in a room of the Istituto Besta. Measurements were carried out during 2 days: on day 1 the patients 
performed the incremental exercise (see below); on day 2 the patients performed a series of 6−min 
constant load exercises of moderate intensity. During each testing day the experimental session 
lasted about 1-1.5 hours. A few minutes before incremental, McA patients ingested 330 mL of 
caffeine−free drink containing 37 g of sucrose (Andersen et al. 2008), in order to increases exercise 
tolerance and peak exercise capacity, and abolishes the “second wind” phenomenon occurring after 
about 10 minutes of exercise (Vissing &Haller 2003).  
Exercise protocol. An electromagnetically braked cycloergometer was utilized. Pedalling frequency 
was digitally displayed to the subjects. Subjects were allowed time to gain familiarity with the 
investigators and with experimental arrangement, and were carefully instructed about the 
experimental procedures. Subjects were also familiarized with the experimental protocol by means 
of short preliminary practice runs. On Day 1, an incremental exercise was performed: after a few 
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minutes of unloaded pedalling, exercise was conducted at 25−50 W for 6 minutes, and thereafter 
the workload was increased by 10−25 W (according to the subject’s estimated level of physical 
fitness) every minute until voluntary exhaustion will be reached. The latter was be defined by: 1) 
inability to maintain the pedalling frequency (60−80 revolutions/min) despite encouragement by the 
operators; 2) maximal levels of self−perceived exertion, using the validated Borg’s scale (Borg 
1982); and 3) heart rate (HR) values higher than 85% of the age−predicted maximum. On Day 2, 
the patients performed 3 repetitions of 6−min constant−load moderate−intensity exercise (CWR-
LOW). The work rate was chosen to correspond to about 50% of peak workload reached during the 
incremental exercise before training. Repetitions were separated by at least 30 min recovery 
periods. Relatively long recovery periods were chosen a) to be sure that patients were in resting 
conditions before the next exercise bout; b) to avoid the occurrence of a ‘‘second-wind 
phenomenon’’ in McArdle patients (REF); and c) to avoid a ‘‘priming effect’’ on V˙O2 kinetics 
(REF). On Day 3, MM performed also 1 repetitions of constant−load heavy−intensity exercise at 
exhaustion(CWR-HIGH). The work rate was chosen to correspond to about 75% of peak workload. 
Transitions from unloaded pedaling to the imposed load were attained in approximately 3 s.  
Measurements. All tests were carried out under close medical supervision, and patients were 
monitored by 12-lead electrocardiography (ECG). An electromagnetically braked cycle ergometer 
(Corival, Lode, The Netherlands) was utilized. Pedalling frequency was digitally displayed to the 
patients. Patients were allowed time to gain familiarity with the investigators and experimental 
arrangement, and were carefully instructed. Pulmonary ventilation (V˙E), V˙O2, and CO2 output 
(V˙CO2) were determined breath-by-breath by a computerized metabolic cart (Vmax229; 
SensorMedics, The Netherlands). Heart rate was determined from the ECG signal. Arterial blood 
O2 saturation (SaO2) was monitored continuously by pulse oximetry (Biox 3740 Pulse Oximeter; 
Ohmeda, Italy) at the earlobe. Stroke volume was estimated beat-by-beat by impedance 
cardiography (Physio Flow; Manatec, France). The accuracy of this device has been previously 
evaluated during incremental exercise in healthy subjects against the direct Fick method and this 
method has been utilized by our group in other studies (REF.). CO was calculated as HR*SV. At 
rest and at various time-points (1, 3, 5 and 7 minutes) during recovery after exercise, 20 µl of 
capillary blood was obtained from a pre-heated earlobe for the determination of blood lactate 
concentration ([La]b) by an enzymatic method (Biosen 5030; EKF Eppendorf , Italy). The highest 
[La]b value obtained during recovery was considered [La]b peak.  
Oxygenation changes in the vastus lateralis muscle were evaluated by near-infrared spectroscopy 
(NIRS) (Boushel R, Langberg H, Olesen J, Gonzales-Alonso J, Bülow J, Kjær M. Monitoring tissue 
oxygen availability with near infrared spectroscopy in health and disease. Scand J Med Sci Sports 
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11: 213–222, 2001, Ferrari M, Mottola L, Quaresima V. Principles, techniques, and limitations of 
near-infrared spectroscopy. Can J Appl Physiol 29: 463–487, 2004). A portable NIR continuous-
wave photometer (PortaMon, Artinis, The Netherlands) was utilized. Specific details on the method 
can be found in recent papers by our group (Porcelli S, Marzorati M, Lanfranconi F, Vago P, Pišot 
R, Grassi B. Role of skeletal muscles impairment and brain oxygenation in limiting oxidative 
metabolism during exercise after bed rest. J Appl Physiol 109:101–111, 2010, Porcelli S, Marzorati 
M, Belletti M, Bellistri G, Morandi L, Grassi B. The “second wind” in McArdle’s disease patients 
during a second bout of constant work rate submaximal exercise. J Appl Physiol 116: 1230–1237, 
2014). The instrument measures micromolar (µM) changes in oxygenated hemoglobin (Hb) + 
myoglobin (Mb) concentrations (Δ[oxy(Hb+Mb)]), and in deoxygenated [Hb + Mb] 
(Δ[deoxy(Hb+Mb)]), with respect to an initial value arbitrarily set equal to zero and obtained during 
the resting condition preceding the test. Δ[deoxy(Hb+Mb)] is relatively insensitive to changes in 
blood volume and has been considered an estimate of skeletal muscle fractional O2 extraction (ratio 
between O2 consumption and O2 delivery) (Ferreira LF, Poole DC, Barstow TJ. Muscle blood 
flow-O2 uptake interaction and their relation to on-exercise dynamics of O2 exchange. Respir 
Physiol Neurobiol 147: 91–103, 2005). Reliability of tissue oxygenation indexes obtained by NIRS, 
evaluated by the intraclass correlation coefficient for repeated measurements on the same subject 
during different days, was found to be very high for skeletal muscle (Subudhi AW, Dimmen AC, 
Roach RC. Effects of acute hypoxia on cerebral and muscle oxygenation during incremental 
exercise. J Appl Physiol 103: 177–183, 2007). A “physiological calibration” of Δ[deoxy(Hb+Mb)] 
values was performed by obtaining a transient ischemia of the limb after the exercise period 
(subject in the sitting position on the cycloergometer): data obtained during exercise were expressed 
as a percentage of the values of maximal muscle deoxygenation obtained by pressure cuff inflation 
(at 300–350 mmHg), carried out at the inguinal crease of the thigh for a few minutes until 
Δ[deoxy(Hb+Mb)] increase reached a plateau (Grassi B, Pogliaghi S, Rampichini S, Quaresima V, 
Ferrari M, Marconi C, Cerretelli P. Muscle oxygenation and gas exchange kinetics during cycling 
exercise on-transition in humans. J Appl Physiol 95:149–158, 2003). 
Kinetics analysis. V O2 kinetics were evaluated during transitions from unloaded pedaling to 
constant load exercise. Breath-by-breath V O2 values obtained in the various repetitions of the 
exercise were time aligned and then superimposed for each subject. Average V O2 values every 10 s 
were calculated. Data obtained during the first 20 s of the transition (‘‘cardiodynamic’’ phase 
[Whipp BJ, Rossiter HB, Ward SA. Exertional oxygen uptake kinetics: a stamen of stamina? 
Biochem Soc Trans. 2002;30:237–47]) were excluded from analysis. Thus, V O2 kinetics analysis 
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dealt mainly with the ‘‘phase 2’’ (or ‘‘fundamental’’ component) of the response, which more 
closely reflects gas exchange kinetics occurring in skeletal muscles (Grassi B, Poole DC, 
Richardson RS, Knight DR, Erickson BK, Wagner PD. Muscle O2 uptake kinetics in humans: 
implications for metabolic control. J Appl Physiol. 1996;80:988–98). To evaluate mathematically 
the V O2 kinetics, data were fitted by the function:  
y(t) = yBAS + Af [-e (t-TDf)/τf],                                       [1] 
and parameter values (TDf, τf) were determined that yielded the lowest sum of squared residuals. In 
equation 1, yBAS indicates the baseline; Af is the amplitude between the yBAS and the steady state 
during the fundamental component; and TDf is the time delay and τf is the time constant of the 
function for the fundamental component. To check the presence of a ‘‘slow component’’ (Whipp 
BJ, Rossiter HB, Ward SA. Exertional oxygen uptake kinetics: a stamen of stamina? Biochem Soc 
Trans. 2002;30:237–47) of the kinetics, data were also fitted by the function: 
y(t) = yBAS + Af [-e (t-TDf)/τf] + As [-e (t-TDs)/τs] [2] 
In equation 2, As, TDs, and Ts indicate, the amplitude, the time delay, and the time constant of the 
slow component, respectively. 
 
Statistical analysis. Results were expressed as mean values ± Standard Deviation (x ± SD). 
Comparisons between patients before and after the training program were performed by two−sided 
Student’s t−test. Comparisons between more than two observations were performed by one−way 
ANOVA; a Tukey’s post−hoc test was utilized when significant differences emerged at ANOVA. 
Data fitting by linear regression or by other functions was performed by the least squared residuals 
method. Comparisons between fittings with different functions models were performed by F test. 
The level of significance was set at P<0.05. Statistical analyses were performed by a software 
package (Prism 5.0, GraphPad). 
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RESULTS 
Training. Overall the compliance to the training regimen was rated as “very good”. The work rate 
of the first two (START) and the last three (END) training sessions that patients carried at their 
homes is shown in Figure 2. There was a significantly increase of the mean work rate of the 
training sessions in both MM and McA.  
 
Incremental exercise. Peak values of the main respiratory, cardiovascular and metabolic variables 
are shown in Table 1. In McA and MM, values obtained before training were very similar to those 
obtained in a previous study by our group (14) and by others (19,21). After training,  an increase of 
∼20% in work rate and O2 peak values were observed both in MM and McA, indicating a 
severely improved exercise capacity. SV and Q
.
 peak values were also significantly increased both 
in McA and MM, reaching values slightly lower than those usually obtained in healthy controls 
(39). HR peak were significantly higher in McA vs. MM, corresponding respectively to ~83% and  
~96% of the age–predicted maximum. Aerobic training also improved peak skeletal muscle 
fractional O2 extraction capacity, even if values were very low for both patients groups. As 
expected, in McA R peak values were relatively low, and [La]b peak values were not higher than 
those determined at rest (1.2 ± 0.1 mM). For the other variables no differences were observed after 
training both in McA and MM.  
 
Moderate-intensity constant work rate exercise. Mean (± SD) values determined in the last ~30 s 
of CWR-LOW are presented in Table 2. O2, E, HR, Q
.
 and RPE values were significantly 
reduced after training, both in MM and McA. On the other hand, ∆[deoxy(Hb+Mb)] was 
significantly higher in AFTER vs. BEFORE. For the other variables no differences were observed 
between BEFORE and AFTER both in MM and McA.  
 
Heavy-intensity constant work rate exercise. Figure 3 shows O2, Q
.
 and ∆[deoxy(Hb+Mb)] 
values BEFORE and AFTER training in MM. After training, O2 was significanly reduced. A 
significant reduction was also observed for CO2 (1.12±0.2 in BEFORE and 0,98±0.1 in AFTER), 
E (45.2±7,6 in BEFORE and 38.5±6.8 in AFTER) and R (1.1±0.1 in BEFORE and 1.0±0.1 in 
AFTER) values. As for cardiovascular response to exercise, HR values at the end of CWR-HIGH 
were lower (by about 10 beats . min-1) in AFTER (120.8±9.2 b*min-1) than in BEFORE 
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(134.3±10.8 b*min-1). Q
.
 values were also significantly reduced (Fig. 3). On the contrary, peak 
skeletal muscle fractional O2 extraction capacity significantly increased after training. In AFTER, 
the time of exhaustion (10,0±0,6 min) was slightly higher than BEFORE (9,2±0,7 min) and a lower 
scores at the Borg’s scale of perceived exertion was observed (from 14.5 ± 1.2 to 12.3 ± 1.5).   
 
O2 kinetics. Typical individual examples of O2 kinetics of a MM (upper panels) and of a McA 
(lower panels) during CWR-LOW are shown in Figure 4. In MM, a slow component was not 
observed both in BEFORE and AFTER. As for McA, O2 values did not reach a steady-state and a 
slow component was evident BEFORE. The parameters of O2 kinetics are shown in Table 3. In 
MM τf and Af values were significantly reduced in AFTER vs. BEFORE. In McA TDf, τf and Af 
values were not affected by training. However, a slow component, corresponding to ~16 % of the 
total amplitude of the response, was present in all McA in BEFORE. After training, the amplitude 
of the slow component was significantly reduced in two patients and it disappeared in the remaining 
five patients. Gain values (G) were calculated as Δ O2 ( O2 at the end of CWR minus resting 
O2) divided by work rate. In both groups of patients, G values were significantly reduce by training 
intervention even if they remained substantially higher than those usually observed in normal 
subjects (∼10 ml . min-1 . watt-1). 
 
Daily physical activity. TEE was not different BEFORE (36.6 ± 9.2 kcal/day/kg) vs. AFTER (35.7 
± 13.4) training. TEE values corresponded to a “low” level of habitual physical activity according 
to standard classifications. 
 
DISCUSSION 
Mitochondrial myopathies and McArdle’s disease are genetic disorders characterized by 
impairments of energy metabolism which translate into reduced exercise tolerance and easy 
fatigability. In two studies our group have demonstrated that two non−invasive methods of 
functional evaluation specifically aimed to oxidative metabolism at the skeletal muscle level are 
able to characterize the metabolic impairment of these patients. In particular, we showed that, 
skeletal muscle oxygenation indices during exercise, obtained by near−infrared spectroscopy and 
taken as estimates of the capacity of O2 extraction, allows to quantify, noninvasively, the limitation 
to skeletal muscle oxidative metabolism both in MM and McA patients. Moreover, the kinetics of 
adjustment of pulmonary VO2  during transitions to constant-load moderate-intensity exercise were 
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quantitatively correlated with an impaired peak capacity of O2  extraction and with a lower peak 
aerobic power. At present the therapeutic interventions available for these patients are very limited. 
Evidence from the literature suggests that moderate−intensity aerobic exercise training represents a 
safe intervention, which may benefit MM and McA patients by increasing their exercise tolerance. 
In this study, 6 MM and 7 McA patients underwent 12 weeks of home-based exercise training: 4 
training sessions per week; about 1 hour per session; 30-45 minutes of moderate-intensity aerobic 
exercise on a cycle ergometer, at an heart rate (HR) corresponding to about 65-70% of the maximal 
HR. After training, peak O2 uptake (V’O2peak), variable evaluating maximal aerobic power, 
increased significantly both in MM and in McA. The 20% increase in V’O2peak, which is similar 
to that usually described following similar training programs in healthy subjects, demonstrates an 
increased exercise tolerance. Peak skeletal muscle (vastus lateralis) fractional O2 extraction, as 
estimated by near-infrared spectroscopy (NIRS), increased with training both in MM and in McA. 
From these data it can be inferred that the increased V’O2peak with training was attributable, at 
least in part, to an increased skeletal muscle fractional O2 extraction. In a previous study (Grassi et 
al., Muscle Nerve 35: 510-520, 2007) we had demonstrated that the impaired fractional O2 
extraction by skeletal muscles, as evaluated by NIRS, represents a key pathophysiological factor 
both in MM and in McA patients. 
 
Before and at the end of the training period the patients carried out in the lab also constant work rate 
exercises on a cycle ergometer, at moderate intensity (about 50% of V’O2peak) and at heavy 
intensity (65-70% of V’O2peak). During the latter MM patients showed, after training, clear signs 
of increased exercise tolerance, such as lower HR (from 134.3 ± 26.6 b/min to 121.2 ± 21.9), lower 
gas exchange ratio (from 1.11 ± 0.16 to 1.02 ± 0.10), lower scores at the Borg’s scale of perceived 
exertion (from 14.5 ± 1.2 to 12.3 ± 1.5).  
In a previous study we had observed in MM and in McA patients slower than normal pulmonary 
“V’O2 kinetics” (Grassi et al., Med. Sci. Sports Exerc. 41: 2120-2127, 2009) (the term indicates the 
rate of adjustment of pulmonary V’O2 during rest to constant work rate transitions). As pointed out 
in another previous paper by our group (Grassi et al., Eur. J. Appl. Physiol. 111: 345-355, 2011), 
faster V’O2kinetics reflect a better performance of skeletal muscle oxidative metabolism, and are 
associated with lower “O2 deficit” and higher exercise tolerance. We hypothesized that if training 
obtained (as we were expecting) an improvement of skeletal muscle oxidative metabolism, we 
would see faster V’O2 kinetics in the patients after training. We were rather surprised to see only 
non-significant decreases, after training, of the parameter (time-constant [a lower time-constant 
indicates a faster kinetics]) which we utilized to evaluate the V’O2 kinetics: the time constants were 
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indeed 42.3 ± 17.4 s before training vs. 36.9 ± 10.2 s after training in MM (P=0.18), and 39.0 ± 31.3 
s before training vs. 31.9 ± 10.1 after training in McA (P=0.54). However, after we took into 
consideration the 4 patients with a markedly slower V’O2 kinetics before training (as an arbitrary 
cutoff we considered a time-constant of at least 45 s [values in healthy subjects are in the range of 
25-35 s]), we observed after training values (39.7 ± 8.5 s) which were significantly lower than those 
obtained before training (67.7 ± 22.3). In other words, training significantly speeded the V’O2 
kinetics only in the patients who had presented, before training, markedly slow V’O2 kinetics. This 
concept appears compatible with the results of our previous study (Grassi et al., Med. Sci. Sports 
Exerc. 41: 2120-2127, 2009), in which we showed markedly slower V’O2 kinetics only in the 
patients with the most pronounced metabolic impairment. In other words, we demonstrated that the 
analysis of V’O2 kinetics is a valuable functional evaluation tool of the effects of training in MM 
and McA patients with severe metabolic impairment. 
 
The habitual level of physical activity during the day was evaluated by estimating the daily total 
energy expenditure (TEE). Before and about 2 months after the termination of the training period 
the subjects wore a dedicated device (SenseWear Armband) during 3 typical consecutive days. TEE 
was not different before (36.6 ± 9.2 kcal/day/kg) vs. after (35.7 ± 13.4) training; TEE values 
corresponded to a “low” level of habitual physical activity according to standard classifications. In 
other words, the adopted exercise training program, which increased exercise tolerance of the 
patients, did not induce, a couple of months after the termination of the training program, an 
increased level of habitual physical activity. We have no specific data to explain this unexpected 
and rather disappointing finding.  
In conclusions, in MM and McA patients a standardized training program with aerobic exercise of 
moderate intensity, supervised but carried out at home autonomously by the patient, significantly 
increases exercise tolerance. We also demonstrated that a combination of traditional and more 
innovative functional evaluation methods (identified in previous work by our group) can effectively 
detect the functional improvements obtained by training, yielding insights also on the mechanisms 
of the improvements at the pathophysiological level. Surprisingly, the improvements in exercise 
tolerance obtained by the training program did not determine an increase in the habitual level of 
physical activity evaluated a couple of months after the termination of the training program. Further 
studies should be addressed to evaluate specific “innovative” interventions that can also stimulate 
patients at a “motivational” level in order to obtain an increase in the level of habitual physical 
activity.  
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FIGURE 2. Individual work rate (watt) recorded by the bicycle during the first (START) and the 
last three (END) sessions of training.  
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FIGURE 3. Individual values of oxygen consumption (VO2), cardiac output (Q) and peak skeletal 
muscle fractional O2 extraction capacity (Δ[deoxy(Hb+Mb)]) during the heavy-intensity constant 
work rate exercise in MM. Data obtained before (BEFORE) and after (AFTER) training are 
presented 
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FIGURE 4. Typical individual examples of pulmonary O2 uptake ( O2) kinetics during the 
moderate-intensity constant work rate exercise in MM (upper panels) and McA (lower panels). Data 
obtained before (BEFORE) and after (AFTER) training are presented in the left and right panels, 
respectively. The vertical hatched lines indicate the transitions from rest to the imposed work rate. 
The functions fitting the fundamental component (hatched line) and the slow component (continuos 
lines) are shown. A’s/Atot data are also presented. See text for further details.  
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Table 1. Main respiratory, cardiovascular and metabolic variables in MM and McA. Peak values 
obtained during the incremental exercise both before and after 12 weeks of aerobic training 
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Mean (± SD) Values. O2, oxygen uptake; CO2, CO2 output; R, gas exchange ratio; E, 
pulmonary ventilation; Vt, tidal volume; fR, breathing frequency; PetO2, end-tidal O2 partial 
pressure; PetCO2, end-tidal CO2 partial pressure; [La]b, blood lactate concentration; RPE, rate of 
perceived exertion; HR, heart rate; SV, stroke volume; Q
.
, cardiac output; [C(a-v)O2], systemic 
arterial-venous O2 concentration difference; Δ[deoxy(Hb+Mb)], muscle oxygenation index obtained 
by NIRS. #P < 0.05, significantly different from the corresponding value obtained BEFORE. See 
text for further details.  
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Table 2. Main respiratory, cardiovascula and metabolic variables in MM and McA. Mean (±SD) 
values obtained during the moderate-intensity constant load exercise both before and after 12 weeks 
of aerobic training. 
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Mean (± SD) values of O2, oxygen uptake; CO2, CO2 output; R, gas exchange ratio; E, 
pulmonary ventilation; Gain, Δ O2 ( O2 at the end of CLE minus resting O2) divided by work 
rate; [La]b, blood lactate concentration; RPE, rate of perceived exertion; HR, heart rate; SV, stroke 
volume; Q
.
, cardiac output; Δ[deoxy(Hb+Mb)], muscle oxygenation index obtained by NIRS. #P < 
0.05, significantly different from the corresponding value obtained in BEFORE. See text for further 
details. 
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Table 3. V’O2 kinetics parameters for CWR-LOW in MM and McA. Data obtained before 
(BEFORE) and after 12 weeks of training (AFTER) are shown. 
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Mean (± SD) values of baseline (yBAS); time delay (TDf), time constant (τf), amplitude (Af) of the 
fundamental component; actual amplitude (A’s) of the slow component; and total amplitude of the 
response (Atot); Gain, Δ O2 ( O2 at the end of CWR minus resting O2) divided by work rate. 
*P < 0.05, significantly different from the corresponding value obtained in BEFORE. NA = not 
applicable. See text for further details. 
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FINAL CONSIDERATIONS 
The results of the studies reported in this thesis demonstrate that, in patients with metabolic 
myopathies, a functional evaluation of oxidative metabolism carried out at the whole-body and at 
the skeletal muscle level allows to quantify the metabolic impairment and to identify the 
improvements in exercise tolerance following therapies and/or rehabilitation interventions. At the 
same time, the analysis of the physiological and bioenergetic adaptations to exercise in these 
patients offers to physiologists the opportunity to better understand the regulation of basic 
physiological processes and their relationship with systemic adaptations to exercise. In other words, 
the studies presented in this thesis followed a translational approach, “from the research lab to the 
bed side”, applying some methods of functional evaluation of oxidative metabolism, which our 
group and others have developed over the years, to patients with metabolic myopathies. The results 
appear of interest if one considers the expanding role of exercise training as a therapeutic 
intervention in patients with metabolic myopathies. Thus, an integrated/translational approach 
which combines traditional clinical examination and more innovative functional evaluation methods 
should be pursued to gain mechanistic insights into the pathophysiology of these diseases and into 
the effects of therapeutical/rehabilitative interventions.  
The “next steps” will be to evaluate if, in patients with late-onset Pompe disease, a standardized 
home-based exercise training program of moderate-intensity (similar to that utilized in 
Mitochondrial myopathies and McArdle disease and described above) can delay or reverse, at least 
in part, the reduced efficacy of enzyme replacement therapy often described after a few years of 
administration. This study has just started. Moreover, it could be interesting to study the effects of 
dietary interventions on exercise tolerance and quality of life of patients with metabolic myopathies. 
Specifically, we plan to investigate if a hyperproteic-low carbohydrate diet in patients with Pompe 
disease could reduce glycogen deposition and increase the intracellular protein synthesis, thereby 
reducing glycogen accumulation, proteolysis, muscle autophagy and damage. Secondary, we plan to 
determine the efficacy of a short-term (6 days) dietary supplementation of nitrate, a natural 
constituent of the human diet (spinach, beetroot, etc.) which induces vasodilation and thereby 
decreases blood pressure by nitric oxide production, in increasing the metabolic efficiency and 
exercise tolerance in patients with McArdle disease and late-onset Pompe disease. Indeed, recent 
studies indicate that dietary nitrate decreases the O2 cost of exercise and improves intramuscular O2 
delivery-O2 utilization matching, increasing exercise tolerance. These effects would be extremely 
helpful in patients with McArdle or Pompe disease, in whom the reduced exercise tolerance is 
associated with a markedly increased (compared to healthy control subjects) O2 cost of exercise. 
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In conclusion, contemporary biomedical sciences need an integrated and multidisciplinary 
approach. For the development and implementation of biomedical knowledge, investigators 
working in clinical medicine must perform reverse translational investigations at the cellular and 
molecular level. Similarly, physiologists performing basic research must look for opportunities to 
translate their findings to the whole organism, both healthy and pathological.  
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